Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 166548 |
| CHEMBL ID | 264241 |
| CHEBI ID | 55346 |
| SCHEMBL ID | 38292 |
| MeSH ID | M0436249 |
| Synonym |
|---|
| eraxis |
| ver-002 |
| v-echinocandin |
| ecalta |
| (4r,5r)-4,5-dihydroxy-n(sup 2)-((4'-(pentyloxy)-p-terphenyl-4-yl)carbonyl)-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-l-threonyl-(3s,4s)-3-hydroxy-4-methyl-l-proline cyclic (6-1)-peptide |
| ly-303366 |
| anidulafungin |
| ly303366 |
| DB00362 |
| anidulafunginum |
| anidulafungina |
| n-{(2r,6s,9s,11r,12r,14as,15s,16s,20s,23s,25as)-23-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis[(1r)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyc |
| anidulafungine |
| CHEBI:55346 , |
| unii-9hlm53094i |
| 9hlm53094i , |
| anidulafungin [usan:inn:ban] |
| echinocandin b, 1-((4r,5r)-4,5-dihydroxy-n2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-l-ornithine) |
| ver002 |
| d-70013 |
| CHEMBL264241 |
| d70013 , |
| S4286 |
| bdbm50417554 |
| echinocandin b, 1-((4r,5r)-4,5-dihydroxy-n(sup 2)-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-l-ornithine)- |
| anidulafungin [who-dd] |
| anidulafungin [inn] |
| anidulafungin [mart.] |
| (4r,5r)-4,5-dihydroxy-n(sup 2)-((4''-(pentyloxy)-p-terphenyl-4-yl)carbonyl)-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-l-threonyl-(3s,4s)-3-hydroxy-4-methyl-l-proline cyclic (6->1)-peptide |
| anidulafungin [ema epar] |
| anidulafungin [vandf] |
| anidulafungin [orange book] |
| anidulafungin [usan] |
| anidulafungin [mi] |
| CS-1824 |
| HY-13553 |
| n-[[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-tetrahydroxy-bis[(1r)-1-hydroxyethyl]-methyl-hexaoxo-[?]yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide |
| SCHEMBL38292 |
| n-[(3s,6s,9s,11r,15s,18s,20r,21r,24s,25s,26s)-6-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1r)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-18-yl]-4-{4- |
| AKOS030526640 |
| J-010304 |
| mfcd00917070 |
| NCGC00386349-01 |
| SW222238-1 |
| Q4764531 |
| anidulafungin (ly303366) |
| A13436 |
| CCG-270647 |
| 1-((4r,5r)-4,5-dihydroxy-n2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-l-ornithine)-echinocandin b |
| n-[(3s,6s,9s,11r,15s,18s,20r,21r,24s,25s,26s)-6-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1r)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-p |
| EN300-19769052 |
| n-[(3s,6s,9s,11r,15s,18s,20r,21r,24s,25s,26s)-6-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1r)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0,9,13]heptacosan-18-yl]-4'-[4-( |
| n-((2r,6s,9s,11r,12r,14as,15s,16s,20s,23s,25as)-23-((1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl)-2,11,12,15-tetrahydroxy-6,20-bis((1r)-1-hydroxyethyl)-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo(2,1-c:2',1'-l)(1,4,7,10,13,16)hexaazacyc |
| j02ax06 |
| dtxcid90820698 |
| anidulafungin (mart.) |
Anidulafungin is an effective antifungal medicine, which can inhibit activities of candida in vitro and in vivo. It is a new echinocandin that acts by inhibiting (1,3)-beta-D-glucan synthesis in the fungal cell wall.
Anidulafungin is slowly degraded by human peptidases and proteases. It has a low drug-drug interaction profile based on its lack of interaction with the cytochrome P450 system.
Anidulafungin has been shown to be non-inferior to, and possibly more efficacious, than fluconazole in treating patients with invasive candidiasis (IC) The drug has a very long half life, is slowly degraded by human peptidases and proteases and has a low drug-drug interaction profile.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Anidulafungin, which has a very long half life, is slowly degraded by human peptidases and proteases and has a low drug-drug interaction profile based on its lack of interaction with the cytochrome P450 system." | ( [Anidulafungin]. Cantón, E; Gobernado, M, 2008) | 1.98 |
| "Anidulafungin has a wider spectrum of action and lower toxicity than caspofungin." | ( [Role of anidulafungin in solid organ transplant recipients]. Aguado, JM; Ayats, J, 2008) | 1.48 |
| "Anidulafungin has been shown to be non-inferior to, and possibly more efficacious, than fluconazole in treating patients with invasive candidiasis (IC). " | ( Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey. Dinleyici, EC; Kara, A; Kong, DCM; Neoh, CF; Senol, E; Turner, SJ, 2017) | 2.18 |
| "Anidulafungin has been reported to be an effective treatment for candidemia in Western populations, but little is known about its efficacy in Asian patients, where the clinical presentation and epidemiology may be different." | ( Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial. Co, VM; Hsueh, PR; Mootsikapun, P; Ong, ML; Rajadhyaksha, V; Talwar, D, 2013) | 1.49 |
| "Anidulafungin, which has a very long half life, is slowly degraded by human peptidases and proteases and has a low drug-drug interaction profile based on its lack of interaction with the cytochrome P450 system." | ( [Anidulafungin]. Cantón, E; Gobernado, M, 2008) | 1.98 |
| "Anidulafungin has potent activity against a broad spectrum of Candida species, including strains resistant to azoles and amphotericin B." | ( A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. Clark, K; Fichtenbaum, C; Goldstein, BP; Reboli, A; Schranz, JA; Vazquez, JA, 2008) | 1.3 |
| "Anidulafungin has a wider spectrum of action and lower toxicity than caspofungin." | ( [Role of anidulafungin in solid organ transplant recipients]. Aguado, JM; Ayats, J, 2008) | 1.48 |
| "Anidulafungin has showed its efficacy and good tolerability in systemic candidiasis of non-neutropenic adults, including candidemia especially in fragile patients." | ( [Anidulafungin: a new therapeutic option in systemic candidiasis]. Lanternier, F; Lortholary, O, 2010) | 1.99 |
| "Anidulafungin has potent in vitro activity against Candida and Aspergillus species, predictable pharmacokinetics that does not require dosage adjustment, few drug interactions and is well tolerated." | ( Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections. Kuti, EL; Kuti, JL, 2010) | 1.32 |
| "Anidulafungin has excellent activity against Candida species, but the pharmacokinetics (PK) and safety of the drug in infants and neonates are unknown." | ( Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Aram, J; Benjamin, DK; Capparelli, E; Cheifetz, IM; Cohen-Wolkowiez, M; Hope, WW; Kashuba, AD; Liu, P; Moran, C; Piper, L; Smith, PB; Walsh, TJ, 2011) | 1.35 |
| "Anidulafungin has no significant drug interactions at all." | ( Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. Kofla, G; Ruhnke, M, 2011) | 1.38 |
| "Anidulafungin has potent in vitro activity against Aspergillus and Candida spp, including those resistant to either fluconazole or amphotericin B. " | ( Anidulafungin: a new echinocandin with a novel profile. Vazquez, JA, 2005) | 3.21 |
| "Anidulafungin has potent in vitro activity against C." | ( In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Burgess, DS; Carden, M; Cota, J; Graybill, JR; Najvar, LK; Wiederhold, NP, 2006) | 1.35 |
| "Anidulafungin has been approved for treatment of candidaemia, intra-abdominal abscesses, peritonitis and oesophageal candidiasis." | ( Anidulafungin--state of affairs from a clinical perspective. Cornely, OA; Karthaus, M; Kümmerle, T; Vehreschild, JJ, 2007) | 2.5 |
Anidulafungin as first-line treatment of C/IC appears to be of particular benefit to ICU patients, improving clinical outcomes and possibly decreasing costs. Treatment resulted in higher antifungal drug costs but lower overall costs due to reductions in other medical costs.
Anidulafungin was found to be effective and safe in adult patients with IC/candidemia with ‘recent’ or ‘past’ history of solid tumors. Studies evaluating the use of anidulfungin in combination with other commonly used drugs have not demonstrated any significant drug-drug interactions or adverse events.
Anidulafungin was assayed in plasma, and pharmacokinetic parameters were determined. No dose adjustment is needed even in patients receiving standard intermittent haemodialysis.
We studied the antifungal activity of anidulafungin (AFG) in combination with voriconazole (VRC) against experimental invasive pulmonary aspergillosis (IPA) in persistently neutropenic rabbits. In vitro studies and clinical studies were performed to evaluate the effect on cyclosporine metabolism.
Anidulafungin offers significant promise for antifungal infections. Drug is not metabolized by or eliminated through the kidney. No need for dosage adjustment for any degree of renal or hepatic failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The 1-mg/kg dosage maintained plasma drug levels above the MIC for 18 h, and dosages of >/=5 mg/kg maintained plasma drug levels above the MIC for the entire 24-h dosing interval." | ( Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Bacher, J; Bell, A; Callender, DP; Groll, AH; McMillian, CL; Petraitiene, R; Petraitis, V; Schaufele, RL; Sein, T; Walsh, TJ, 1998) | 0.3 |
| " Oral therapy with ravuconazole at a dosage of 30 mg/kg of body weight per day or the echinocandin LY-303366, given intravenously in a dosage of 5 or 10 mg/kg, was begun 24 h after a lethal or sublethal challenge, and results were compared with those for amphotericin B therapy and untreated controls." | ( Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Andriole, VT; Marino, S; Roberts, J; Schock, K, 2000) | 0.31 |
| " Esophageal tissue VER-002 concentrations were dosage proportional and exceeded the MIC at all dosages." | ( Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Bacher, J; Francesconi, A; Groll, AH; Lyman, CA; Petraitiene, R; Petraitis, V; Piscitelli, SC; Schaufele, RL; Sein, T; Walsh, TJ, 2001) | 0.31 |
| " Except for a significant prolongation of the terminal half-life and a trend toward an increased V(ss) at the higher end of the dosage range after multiple doses, no significant differences in pharmacokinetic parameters were noted in comparison to single-dose administration." | ( Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Bacher, JS; Groll, AH; Lyman, CA; Mickiene, D; Petraitiene, R; Petraitis, V; Piscitelli, SC; Walsh, TJ, 2001) | 0.57 |
| " This indicates that dosing adjustments are not necessary when anidulafungin is administered in the presence of medications falling into these classifications." | ( Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. Dowell, JA; Henkel, T; Knebel, W; Krause, D; Ludden, T; Stogniew, M, 2004) | 0.83 |
| " Against Candida anidulafungin exhibits concentration-dependent killing and clearance of residual fungal burden in target organs (liver, lung, spleen, kidney) and plasma/tissue concentrations exceed the minimum inhibitory and minimum fungicidal concentrations of the infecting organism throughout the dosing interval." | ( Anidulafungin: an echinocandin antifungal. Pfaller, MA, 2004) | 2.11 |
| " Across the dosage range 50-100 mg/day, adverse events appear not to be dose- or infusion-related." | ( Anidulafungin. Murdoch, D; Plosker, GL, 2004) | 1.77 |
| " A favorable pharmacokinetic profile and lack of significant drug interactions suggest that patients can receive anidulafungin without dosage adjustments." | ( Anidulafungin: review of a new echinocandin antifungal agent. Raasch, RH, 2004) | 1.98 |
| " The echinocandins are targeted for once-daily dosing and are not metabolized through the cytochrome P450 enzyme system, and they are generally well tolerated due to lack of mechanism-based toxicity." | ( Pharmacokinetics/pharmacodynamics of echinocandins. Theuretzbacher, U, 2004) | 0.32 |
| " A small increase in anidulafungin concentrations and drug exposure (22%) was observed after 4 days of dosing with cyclosporine and was not considered to be clinically relevant." | ( Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. Dowell, JA; Henkel, T; Krause, D; Stogniew, M; Weston, IE, 2005) | 0.9 |
| " Pharmacokinetic parameters were determined for 12 patients at each dosage (0." | ( Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Benjamin, DK; Clark, K; Dowell, JA; Driscoll, T; Gonzalez, CE; Kilaru, R; Roden, MM; Schranz, J; Seibel, NL; Walsh, TJ, 2006) | 0.6 |
| "The chemistry, pharmacology, spectrum of activity, resistance, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse effects, drug interactions, dosage and administration, cost, and place in therapy of echinocandins are reviewed." | ( Echinocandins in the management of invasive fungal infections, Part 2. Morris, MI; Villmann, M, 2006) | 0.33 |
| " Echinocandins are poor substrates of the cytochrome P450 enzyme family and can be safely co-administered with most drugs without the need for dosage adaptation." | ( The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Graninger, W; Joukhadar, C; Presterl, E; Wagner, C, 2006) | 0.33 |
| " Anidulafungin can be safely administered to patients with any degree of hepatic or renal impairment without dosage adjustment and without regard to hemodialysis schedules." | ( Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. Damle, B; Dowell, JA; Krause, D; Stogniew, M, 2007) | 2.69 |
| " The kinetics following intraperitoneal anidulafungin dosing in neutropenic infected mice were monitored." | ( In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Andes, D; Ashbeck, J; Diekema, DJ; Hou, J; Marchillo, K; Pfaller, MA; Prince, RA, 2008) | 0.87 |
| " It does not require dosage adjustment in subjects with hepatic or renal impairment established." | ( [Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin]. Catalán González, M; Montejo González, JC, 2008) | 1.26 |
| " The limited toxicity profile, minimal drug-drug interactions and the fact that does not require dosage adjustment in subjects with hepatic or renal impairment, establishes this echinocandin as an attractive new option for the treatment of invasive fungal infections." | ( [Therapeutic efficacy of anidulafungin for the treatment of oesophageal candidiasis, candidemia and invasive candidiasis]. Catalán González, M; León Gil, C; Montejo González, JC, 2008) | 0.65 |
| " Thus, dosing adjustments of anidulafungin based on age, gender, body weight, disease status, concomitant therapy or renal or hepatic insufficiency is not necessary." | ( [Anidulafungin]. Cantón, E; Gobernado, M, 2008) | 1.55 |
| " without bisecting any species group and represent a concentration that is easily maintained throughout the dosing period." | ( Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. Alexander, BD; Andes, D; Brown, SD; Chaturvedi, V; Diekema, DJ; Ghannoum, MA; Knapp, CC; Ostrosky-Zeichner, L; Pfaller, MA; Rex, JH; Sheehan, DJ; Walsh, TJ, 2008) | 0.57 |
| " Anidulafungin is not associated with any drug-drug interactions and does not require dosage adjustment in patients with renal and/or hepatic impairment." | ( Anidulafungin: a drug evaluation of a new echinocandin. Joseph, JM; Kim, R; Reboli, AC, 2008) | 2.7 |
| " Since VOR is metabolized more rapidly in rodents than in humans, dosage adjustment for VOR is necessary to obtain an area under the plasma concentration-time curve (AUC) in rodents that is equivalent to that of humans." | ( Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Bakker-Woudenberg, IA; Mathot, RA; Rijnders, BJ; Tavakol, M; ten Kate, MT; van de Sande, WW; van Vianen, W, 2009) | 0.55 |
| " We concluded that the combination of AFG with VRC in treatment of experimental IPA in persistently neutropenic rabbits was independent to synergistic at a dosage of 5 mg/kg/day but independent to antagonistic at 10 mg/kg/day, as assessed by Bliss independence analysis, suggesting that higher dosages of an echinocandin may be deleterious to the combination." | ( Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Avila, NA; Bacher, J; Cotton, MP; Francesconi, A; Hope, WW; Hughes, JE; Kasai, M; Meletiadis, J; Mickiene, D; Petraitiene, R; Petraitis, V; Schaufele, RL; Sein, T; Stergiopoulou, T; Walsh, TJ, 2009) | 0.55 |
| " Sensitivity analyses included dosage forms of amphotericin B and fluconazole compared to other azoles." | ( Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis. Cooper, C; Mills, EJ; Nachega, JB; Perri, D; Phillips, P; Tleyjeh, I; Wu, P, 2009) | 0.35 |
| " Specifically, this new drug has a greater volume of distribution, a higher elimination half-life and, moreover, an elimination system -- spontaneous degradation --, thus avoiding interactions with other drugs and allowing its use without dosage adjustments in patients with renal or liver impairment." | ( [Pharmacokinetics and pharmacodynamics: interactions and adverse effects. Comparison with other echinocandins]. Azanza, JR; Montejo, M, 2008) | 0.35 |
| " One of the most interesting features of anidulafungin in solid organ transplant recipients is that this drug is not metabolized by or eliminated through the kidney so that dosage adjustments are not required in these patients, who frequently show renal function alterations." | ( [Role of anidulafungin in solid organ transplant recipients]. Aguado, JM; Ayats, J, 2008) | 1.03 |
| " Drug penetration was determined by the ratio of the total drug area under the concentration-time curve during the dosing interval (AUC(0-tau)) for epithelial lining fluid (ELF) and alveolar macrophages (AM) to the total drug AUC(0-tau) in plasma." | ( Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Banevicius, MA; Crandon, JL; Crownover, PH; Fang, AF; Knauft, RF; Kuti, JL; Nicolau, DP; Pope, JS; Russomanno, JH; Shore, E, 2009) | 0.59 |
| ", pediatric dosing guidelines, and an adult indication for echinocandin use in candidal peritonitis, there are no reports of echinocandin use for fungal peritonitis in pediatric patients." | ( Neonatal peritoneal candidiasis successfully treated with anidulafungin add-on therapy. Benner, KW; Prabhakaran, P; Varisco, BM, 2009) | 0.6 |
| " The newest echinocandin, anidulafungin, offers significant promise for antifungal infections, and has a number of favourable features, including a lack of known drug interactions and no need for dosage adjustment for any degree of renal or hepatic failure." | ( Pharmacological properties of antifungal drugs with a focus on anidulafungin. Mazzei, T; Novelli, A, 2009) | 0.89 |
| " Anidulafungin is a well tolerated echinocandin with a favorable pharmacokinetic profile; in particular, its lack of hepatic metabolism and renal excretion enables drug administration without dosage adjustment to subjects with any degree of impaired hepatic or renal function." | ( Conclusions. Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections. De Bellis, P, 2009) | 1.63 |
| " Its pharmacokinetic properties allow its administration without dosage adjustments in patients with hepatic and renal impairment and account for the absence of drug interactions." | ( [Anidulafungin: a new therapeutic option in systemic candidiasis]. Lanternier, F; Lortholary, O, 2010) | 1.27 |
| " Anidulafungin has potent in vitro activity against Candida and Aspergillus species, predictable pharmacokinetics that does not require dosage adjustment, few drug interactions and is well tolerated." | ( Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections. Kuti, EL; Kuti, JL, 2010) | 1.51 |
| "5 mg/kg/day have anidulafungin exposure levels similar to those in children receiving similar weight-based dosing and in adult patients receiving 100 mg/day." | ( Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Aram, J; Benjamin, DK; Capparelli, E; Cheifetz, IM; Cohen-Wolkowiez, M; Hope, WW; Kashuba, AD; Liu, P; Moran, C; Piper, L; Smith, PB; Walsh, TJ, 2011) | 0.97 |
| " Differences between the three echinocandins with regard to the route of metabolism, requirement for a loading dose, dose adjustment in patients with moderate to severe hepatic disease and different dosing schedules for different types of Candida infections have to be considered." | ( Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. Kofla, G; Ruhnke, M, 2011) | 0.66 |
| "Study design challenges included animal selection, route, dose, age, and duration of dosing in relation to brain maturity, and appropriate study endpoints." | ( Juvenile toxicity assessment of anidulafungin in rats: an example of navigating case-by-case study design through scientific and regulatory challenges. Bowman, CJ; Chmielewski, G; Cross, DM; Lewis, E; Ripp, S; Sawaryn, CM, 2011) | 0.65 |
| " Anidulafungin is unique in that it possesses no clinically relevant drug interactions and does not require dosage adjustment in renal or hepatic impairment." | ( Anidulafungin: when and how? The clinician's view. George, J; Reboli, AC, 2012) | 2.73 |
| " AFG also showed a dose-response efficacy in reducing tissue burden in kidneys and spleen." | ( Efficacy of anidulafungin against Aspergillus niger in vitro and in vivo. Calvo, E; Guarro, J; Mayayo, E; Pastor, FJ, 2011) | 0.75 |
| " Because of the prolonged PAFE of these echinocandins, especially ANF and CAS, less frequent dosing during therapy of Cpa and Cgl infections could be considered." | ( Post-antifungal effects and time-kill studies of anidulafungin, caspofungin, and micafungin against Candida glabrata and Candida parapsilosis. Baltch, A; Bopp, LH; Michelsen, PP; Ritz, WJ; Smith, RP, 2011) | 0.62 |
| "The overall cost impact was evaluated by varying the percentage dosage required of each candin in different possible scenarios." | ( [Cost analysis of 3 candins in the treatment of invasive candidiasis in adult non-neutropaenic patients in Spain]. Barrueta, JA; Casado, MA; García-Vargas, M; Mir, N, ) | 0.13 |
| " Anidulafungin exerted a rapid antifungal effect that was apparent in the first dosing interval." | ( Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. Benjamin, DK; Cohen-Wolkowiez, M; Felton, TW; Goodwin, J; Gregson, L; Hope, WW; Howard, S; Livermore, J; Petraitiene, R; Petraitis, V; Sharp, A; Walsh, TJ; Warn, PA, 2012) | 2.73 |
| " This article provides an update, based on the latest scientific evidence, of the clinical efficacy, pharmacokinetics, safety and dosing of antifungal drugs administered in the management of Candida spp." | ( [Antifungal therapy update: new drugs and medical uses]. Fortún, J, 2011) | 0.37 |
| " Postnatal day (PND) 4 and PND 8 Fischer (F344/DuCrl) rats were dosed subcutaneously once with anidulafungin (10 mg/kg) or once daily for 5 days (PND 4-8)." | ( Tissue distribution of anidulafungin in neonatal rats. Aram, JA; Bowman, CJ; Chmielewski, G; Conte, U; Cross, DM; Gao, H; Lewis, EM; Lin, J; Liu, P; Ripp, SL; Schlamm, HT, 2012) | 0.91 |
| " Juvenile rats were not more sensitive to each drug dosed alone compared with adult rat data on the single drugs." | ( Non-clinical safety assessment and toxicokinetics of voriconazole and anidulafungin in the juvenile rat: a combination study design in support of a Paediatric Investigation Plan. Bowman, CJ; Chmielewski, G; Cross, DM; Lewis, EM; Liu, L; Modesitt, MS; Ripp, SL; Sawaryn, CM, 2012) | 0.61 |
| " Additionally, PAO supports could be moved between agar plates containing different concentrations of echinocandins to change dosage and to investigate the recovery of fungal microcolonies from these drugs." | ( Microcolony imaging of Aspergillus fumigatus treated with echinocandins reveals both fungistatic and fungicidal activities. Ingham, CJ; Schneeberger, PM, 2012) | 0.38 |
| " The analysis showed that the same dosing regimen of anidulafungin can be administered to all patients regardless of body weight." | ( Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections. Liu, P, 2013) | 0.89 |
| " Intensive plasma sampling was performed over a dosing interval at steady state from 21 ICU patients with candidemia/invasive candidiasis." | ( Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis. Damle, B; Kantecki, M; Liu, P; Meersseman, W; Paiva, JA; Ruhnke, M, 2013) | 0.71 |
| " In specific clinical situations when altered pharmacokinetics can be expected or dosing guidelines are conflicting, it may be useful to measure concentrations." | ( Simultaneous quantification of anidulafungin and caspofungin in plasma by an accurate and simple liquid chromatography tandem mass-spectrometric method. Alffenaar, JW; Greijdanus, B; Santoe, RN; Uges, DR; van der Elst, KC; van Hateren, K; van Wanrooy, MJ; Wessels, AM; Wilmer, CM, 2013) | 0.68 |
| " Antimicrobial pharmacokinetics is affected by CRRT, but few studies have addressed the optimal dosage for anidulafungin during CRRT." | ( Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration. Aguilar, G; Azanza, JR; Badenes, R; Belda, FJ; Carbonell, JA; Ferrando, C; Garcia-Marquez, C; Gencheva, G; Gutierrez, A; Marti, FJ; Miñana, A; Navarro, D; Parra, MA; Puig, J; Sadaba, B, 2014) | 2.06 |
| ", the average area under the curve over a 12-hour dosing interval [AUC0-12] at steady state was 46% higher); while it is not definitive, age and concomitant medications may impact this difference." | ( Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Liu, P; Mould, DR, 2014) | 0.65 |
| "This study aimed to investigate the probability of target attainment (PTA) of various anidulafungin dosing regimens against Candida spp." | ( Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia. Doan, TN; Kirkpatrick, CM; Kong, DC; Patel, K; Spencer, A; Walker, P, 2014) | 0.87 |
| "Reduced-frequency dosing strategies of anidulafungin may offer a more convenient way of providing adequate antifungal prophylaxis to patients at high risk of invasive fungal diseases." | ( A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. Blijlevens, NM; Brüggemann, RJ; Burger, DM; Colbers, A; Donnelly, JP; Hol, S; Knibbe, CA; Van Der Velden, WJ, 2015) | 0.95 |
| "We now have sufficient evidence to start using less frequent dosing regimens and demonstrate their value in clinical practice." | ( A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. Blijlevens, NM; Brüggemann, RJ; Burger, DM; Colbers, A; Donnelly, JP; Hol, S; Knibbe, CA; Van Der Velden, WJ, 2015) | 0.68 |
| " Other animals, termed 'vulnerable' animals (n = 3 at 3 mg/kg and those dosed at 6 mg/kg (n = 6)), experienced greater than 60% decrease in CO (-66." | ( Cardiac response to centrally administered echinocandin antifungals. Cleary, JD; Stover, KR, 2015) | 0.42 |
| "This study aimed to investigate the cumulative fraction of response of various echinocandin (caspofungin, micafungin and anidulafungin) dosing regimens against Candida spp." | ( Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients. Ge, T; Liao, S; Xu, G; Yang, J; Zhu, L, 2015) | 0.62 |
| " Consistent with currently approved echinocandins, CD101 demonstrates a low potential for resistance development, which could be further enhanced in vivo by the high maximum concentration of drug in serum (Cmax)/area under the concentration-time curve (AUC) plasma drug exposure achieved with once-weekly dosing of CD101." | ( Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species. Almaguer, AL; Bartizal, K; Locke, JB; Zuill, DE, 2016) | 0.43 |
| " New dosing intervals are being explored to allow less frequent intravenous dosing in the ambulatory setting, and a new long-acting echinocandin, CD101, is being developed for weekly and topical administration." | ( New developments and directions in the clinical application of the echinocandins. Chang, CC; Chen, SC; Slavin, MA, 2017) | 0.46 |
| " Recent studies found no need for dosage adjustment in patients with end-stage renal disease receiving hemodialysis, or patients with AKI receiving continuous venovenous hemofiltration." | ( Filter Adsorption of Anidulafungin to a Polysulfone-Based Hemofilter During CVVHD In Vitro. Graf, BM; Gruber, M; Ittner, KP; Kolbinger, P; Roth, G, 2018) | 0.8 |
| " We combined data from obese subjects with data from normal-weight subjects and determined an optimal dosing regimen for obese patients by population pharmacokinetic modeling." | ( Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults. Brüggemann, RJ; Burger, DM; Knibbe, CA; Lempers, VJ; Ter Heine, R; van Dongen, EP; Wasmann, RE, 2018) | 0.8 |
| " Postantifungal effect (PAFE) is relevant for establishing dosage schedules in antifungal therapy, as the frequency of antifungal administration could change depending on PAFE." | ( Postantifungal effect of anidulafungin against Candida albicans, Candida dubliniensis, Candida africana, Candida parapsilosis, Candida metapsilosis and Candida orthopsilosis. Eraso, E; Gil-Alonso, S; Jauregizar, N; Quindós, G, 2019) | 0.82 |
| " Minimal fungicidal concentrations, in vitro dose-response and time-kill patterns were determined." | ( Antifungal activity and killing kinetics of anidulafungin, caspofungin and amphotericin B against Candida auris. Berrio, I; Dudiuk, C; Gamarra, S; Garcia-Effron, G; Leonardelli, F; Macedo, D; Marin, A; Morales-Lopez, S; Salcedo, S; Theill, L; Yesid-Rodriguez, J, 2019) | 0.78 |
| " glabrata with a double dosage of anidulafungin (200 mg daily) followed by oral voriconazole." | ( Acquisition of FKS2 mutation after echinocandin treatment of infective endocarditis by Candida glabrata. Corcione, S; D'Avolio, A; De Rosa, FG; Pagani, N; Pasero, D; Sanguinetti, M; Trentalange, A, 2019) | 0.79 |
| " Relationships between anidulafungin exposure and key efficacy end points (global response of success and all-cause mortality) and safety end points (all-cause hepatic or gastrointestinal adverse events) in all patients and separately in pediatric patients and the appropriate dosing regimen for IC treatment in pediatric patients were evaluated." | ( Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis. Benjamin, DK; Cohen-Wolkowiez, M; Leister-Tebbe, H; Liu, P; McFadyen, L; Raber, S; Swanson, R; Tawadrous, M; Xie, R, 2020) | 1.18 |
| "The population pharmacokinetics (PK) of anidulafungin in critically ill patients hospitalized in intensive care units (ICUs) was explored with the intention of evaluating and optimizing dosing regimens." | ( Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability. Apostolidi, S; Apostolopoulou, O; Dimopoulos, G; Dokoumetzidis, A; Kapralos, I; Mainas, E; Meletiadis, J; Neroutsos, E; Sambatakou, H; Siopi, M; Valsami, G, 2021) | 1.17 |
| " Model-based PK simulations have been performed to estimate the probability of target attainment (PTA), given the pharmacokinetic/pharmacodynamic target of free 24-hour area under the free drug concentration-time curve over minimum inhibitory concentration for several dosing regimens." | ( Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability. Apostolidi, S; Apostolopoulou, O; Dimopoulos, G; Dokoumetzidis, A; Kapralos, I; Mainas, E; Meletiadis, J; Neroutsos, E; Sambatakou, H; Siopi, M; Valsami, G, 2021) | 0.91 |
| "Case reports and pharmacokinetic data suggest off-label echinocandin dosing may be needed to reach adequate serum concentrations in obese patients." | ( Influence of Body Weight Category on Outcomes in Candidemia Patients Treated With Anidulafungin. Davis, SL; Hutton, M; Kenney, RM; Vazquez, JA, 2022) | 0.95 |
| "A retrospective cohort was conducted to evaluate hospitalized patients treated for candidemia with anidulafungin at Food and Drug Administration-labeled dosing for at least 72 hours from January 1, 2014, through January 31, 2018." | ( Influence of Body Weight Category on Outcomes in Candidemia Patients Treated With Anidulafungin. Davis, SL; Hutton, M; Kenney, RM; Vazquez, JA, 2022) | 1.16 |
| Class | Description |
|---|---|
| azamacrocycle | A cyclic macromolecule containing one or more nitrogen atoms in place of carbon either as the divalent group NH for the group CH2 or a single trivalent nitrogen atom for the group CH. |
| heterodetic cyclic peptide | A heterodetic cyclic peptide is a peptide consisting only of amino-acid residues, but in which the linkages forming the ring are not solely peptide bonds; one or more is an isopeptide, disulfide, ester, or other bond. |
| semisynthetic derivative | Any organic molecular entity derived from a natural product by partial chemical synthesis. |
| echinocandin | Any one of a family of large lipopeptides that are inhibitors of the enzyme 1,3-beta-glucan synthase, thus damaging fungal cell walls. Echinocandins are fungicidal against most Candida spp and fungistatic against Aspergillus spp. |
| antibiotic antifungal drug | Any antibiotic antifungal agent used to treat fungal infections in humans or animals. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| echinocandin B degradation | 0 | 6 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 (µMol) | 17.5000 | 0.0001 | 1.7740 | 10.0000 | AID544311 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 (µMol) | 17.5000 | 0.0001 | 1.7536 | 10.0000 | AID544318 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 (µMol) | 4.6400 | 0.0002 | 2.4585 | 9.9600 | AID1804171 |
| Cytochrome P450 2C8 | Homo sapiens (human) | IC50 (µMol) | 14.7500 | 0.0008 | 1.8848 | 7.9000 | AID544313; AID544314 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 (µMol) | 17.5000 | 0.0000 | 2.0151 | 10.0000 | AID544317 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 (µMol) | 17.5000 | 0.0000 | 2.8005 | 10.0000 | AID544315 |
| Cytochrome P450 2B6 | Homo sapiens (human) | IC50 (µMol) | 17.5000 | 0.0011 | 3.4186 | 10.0000 | AID544312 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 (µMol) | 17.5000 | 0.0000 | 2.3983 | 10.0000 | AID544316 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID555612 | Antimicrobial activity against Aspergillus niveus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID559883 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 99.9% fungal growth reduction at 8 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID432417 | Antifungal activity against nongerminated Aspergillus terreus assessed as absence of visual fungal growth at 64 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID432651 | Ratio of Cmax in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 1.97 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID351872 | Inhibition of wild-type 1,3-beta-D-glucan synthase KU80delta from Aspergillus fumigatus assessed as incorporation of [3H]glucose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. |
| AID432517 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 3.90 +/- 0.15 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days me | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522737 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 0.25 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID323373 | Antifungal activity against Candida glabrata 05-62 isolate in presence of 5% human serum after 22 hrs by XTT assay | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID432636 | Antifungal activity against Candida albicans 580 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 3.81 +/- 0.33 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days mea | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555610 | Antimicrobial activity against Aspergillus ochraceus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID323284 | Antifungal activity against Candida albicans T32 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID433050 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 0.94 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans 580 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432304 | Antifungal activity against Candida glabrata 513 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531157 | Inhibition of Candida metapsilosis am-2006-0113 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID432672 | Ratio of free-drug Cmax in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 1.25 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID529667 | Antimicrobial activity against Paecilomyces variotii by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Susceptibility testing and molecular classification of Paecilomyces spp. |
| AID432863 | Ratio of free-drug Cmax in Candida glabrata 343420-infected neutropenic ICR/Swiss mouse candidiasis model at 6.9 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 343420 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID518076 | Ratio of fAUC (0 to 24 hrs) in Candida parapsilosis infected neutropenic ICR Swiss mouse to MIC for Candida parapsilosis at static dose after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID525544 | Antimicrobial activity against Fonsecaea nubica isolates after 72 hrs by CLSI M38-A2 protocol method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. |
| AID374337 | Ratio of MIC50 for Candida albicans isolate 0012-025 in presence of 50% human serum to MIC50 for Candida albicans isolate 0012-025 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID324344 | Inhibition of glucan synthase in Candida albicans SC5314 in presence of 10% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID564443 | Drug level healthy human epithelial lining fluid at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions after 4 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID535417 | Antifungal activity against Candida albicans SC5314 expressing wild type FKS1 after 24 hrs by broth microdilution method in presence of 50% human serum | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID544335 | Cmax in human plasma at 100 mg, iv by LC-MS/MS analysis | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID554493 | Antifungal activity against Aspergillus fumigatus H237 expressing rasA gene assessed as abnormal hyphal growth by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. |
| AID326108 | Antifungal activity against Candida krusei after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. |
| AID374343 | Ratio of MIC50 for Candida glabrata isolate 0022-012 in presence of 50% human serum to MIC50 for Candida glabrata isolate 0022-012 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID555806 | Antimicrobial activity against Mycocladus corymbiferus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID559022 | Antifungal activity against Candida albicans infected in mouse assessed as decrease in fungus-induced mortality rate at 5 mg/kg, ip | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID555807 | Antimicrobial activity against Rhizopus oryzae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID535615 | Antifungal activity against Candida albicans 42286 expressing wild type FKS1 after 24 hrs by broth microdilution method in presence of 50% human serum | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID432419 | Antifungal activity against nongerminated Aspergillus flavus assessed as absence of visual fungal growth at 64 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID433032 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 3.57 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID545414 | Antimicrobial activity against Candida albicans isolate S at 1 ug/ml grown on RPMI 1640 medium after 48 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID565360 | Antifungal activity against Candida dubliniensis 10032 after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID570833 | Antifungal activity against Candida glabrata isolate 1 assessed as time period for bacterial growth inhibition at 16 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID525541 | Antimicrobial activity against Fonsecaea isolates after 72 hrs by CLSI M38-A2 protocol method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. |
| AID559667 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 99% fungal growth reduction at 0.12 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID518075 | Ratio of fAUC (0 to 24 hrs) in Candida glabrata infected neutropenic ICR Swiss mouse to MIC for Candida glabrata at static dose after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID323340 | Antifungal activity against Candida parapsilosis ATCC 22019 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID555805 | Antimicrobial activity against Lecythophora hoffmannii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID546073 | Antifungal activity against Candida tropicalis isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID531138 | Antifungal activity against Candida parapsilosis H5 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID433417 | Ratio of free-drug Cmax in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 2.31 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555813 | Antimicrobial activity against Exophiala jeanselmei by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID570838 | Increase in susceptibility to SDS in Candida parapsilosis isolate A assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID535409 | Antifungal activity against Candida albicans 41301 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID374502 | Ratio of MIC50 for Candida parapsilosis ATCC 22019 in presence of 50% human serum to MIC50 for Candida parapsilosis ATCC 22019 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID433667 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 13 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-210 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433685 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans K-1 after 24 h | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374516 | Antifungal activity against Aspergillus fumigatus isolate 0002-0016 after 24 hrs by CLSI M38-A broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID546076 | Antifungal activity against Candida rugosa isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID433430 | Ratio of free-drug Cmax in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 4.21 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432312 | Antifungal activity against Candida glabrata 37661 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432862 | Ratio of free-drug Cmax in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 1.58 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID324345 | Inhibition of glucan synthase in Candida albicans SC5314 in presence of 20% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID544149 | Antimicrobial activity against Candida albicans 90 harboring FKS1 G4082R mutant gene and FKS1 hotspot2 R1361R/H mutant gene by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID531237 | Antifungal activity against Candida guilliermondii after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID433406 | Ratio of Cmax in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 13 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522773 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 1 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID555624 | Antimicrobial activity against Scopulariopsis brevicaulis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID570879 | Antifungal activity against Candida parapsilosis isolate A assessed as cell wall damage at MIC by Transmission electron microscopy | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID425781 | Antifungal activity against Candida albicans GDH2346 grown as planktonic cell assessed as minimum drug level required to decrease turbidity by 50% after 24 hrs by CLSI M27-A2 method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID323364 | Antifungal activity against Candida glabrata 05-62 isolate assessed as decrease in fungal turbidity in presence of 5% human serum by microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID433624 | Antifungal activity against Candida glabrata 32930 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323336 | Antifungal activity against Candida dubliniensis SCSBB417709 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID323370 | Antifungal activity against Candida glabrata 05-761 isolate assessed as decrease in fungal turbidity in presence of 50% human serum by microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID574306 | Fungicidal activity against Candida glabrata isolate 3 assessed as log reduction in bacterial count at 16 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID574337 | Fungicidal activity against Candida glabrata isolate 2 assessed as log reduction in bacterial count at 16 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433429 | Ratio of free-drug Cmax in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 4.13 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433662 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 3.31 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID559668 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 99.9% fungal growth reduction at 0.12 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID374345 | Antifungal activity against Candida glabrata isolate 0049-038 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID323352 | Antifungal activity against Candida glabrata 05-62 isolate after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID325030 | Antifungal activity against Candida krusei 98 isolate from acute myelogenous leukemia patient by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. |
| AID323327 | Antifungal activity against Candida dubliniensis SCS17154969-1 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID374504 | Antifungal activity against Candida tropicalis isolate 0022-021 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID555623 | Antimicrobial activity against Acremonium sp.by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID574104 | Antifungal activity against Candida glabrata isolate 3 by CLSI M27-A3 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID570848 | Increase in susceptibility to SDS in Candida glabrata isolate 3 assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433213 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 34341-infected neutropenic ICR/Swiss mouse candidiasis model at 6.9 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 34341 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522792 | Antifungal activity against Candida albicans 177 harboring FKS1 T1922C mutant gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID433049 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 3.37 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-210 af | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432668 | Ratio of Cmax in Candida glabrata 34341-infected neutropenic ICR/Swiss mouse candidiasis model at 6.9 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 34341 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544167 | Inhibition of Candida albicans 149 1,3-beta-D-glucan synthase subunit FKS1p G1942T mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID433209 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 1.97 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 570 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531140 | Antifungal activity against Candida orthopsilosis 981224 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID555619 | Antimicrobial activity against Fusarium oxysporum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID574347 | Antifungal activity against Candida albicans isolate 1 assessed as time period for bacterial growth inhibition at 4 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432635 | Antifungal activity against Candida albicans 98-210 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 3.81 +/- 0.33 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570840 | Increase in susceptibility to SDS in Candida glabrata isolate 1 assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522794 | Inhibition of Candida tropicalis ATCC 750 wild type FKS | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID565393 | Antifungal activity against Candida dubliniensis FMR 10034 infected in OF1 mouse assessed as fungal count in spleen at 10 mg/kg/day, iv after 24 hrs by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID545204 | Antimicrobial activity against Candida albicans isolate R at 25 ug/ml grown on Muller-Hinton agar medium after 48 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID574340 | Fungicidal activity against Candida glabrata isolate 3 assessed as log reduction in bacterial count at 4 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID574333 | Fungicidal activity against Candida parapsilosis isolate S assessed as log reduction in bacterial count at MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID544413 | Selectivity ratio of Ki for Candida albicans 149 1,3-beta-D-glucan synthase subunit FKS1p G1942T mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID323259 | Antifungal activity against Candida albicans SC5314 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID432330 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as reduction of viral burden in kidney at 1.25 mg/kg, ip administered 2 hrs postinfection as single dose measured after 96 hrs post dosing | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432822 | Ratio of free-drug Cmax in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574103 | Antifungal activity against Candida glabrata isolate 2 by CLSI M27-A3 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522786 | Antifungal activity against wild type Candida tropicalis ATCC 750 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID326105 | Antifungal activity against Candida albicans after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. |
| AID509667 | Antimicrobial activity against Pichia guilliermondii ATCC 6260 after 24 hrs by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID544182 | Activity at Candida albicans 2762 1,3-beta-D-glucan synthase subunit FKS1p T1922C mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID575109 | Antifungal activity against Madurella mycetomatis isolate 43 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID544190 | Activity at Candida albicans 194 1,3-beta-D-glucan synthase subunit FKS1p C1934T/G4082R mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID575112 | Antifungal activity against Madurella mycetomatis isolate 49 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID540210 | Clearance in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID544163 | Inhibition of Candida albicans 205 1,3-beta-D-glucan synthase subunit FKS1p T1933C mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID432502 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 3.90 +/- 0.15 log10CFU per kidney administered intraperitoneally every 16 hrs up to 4 days mea | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432839 | Ratio of free-drug Cmax in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 3.57 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574311 | Fungicidal activity against Candida krusei isolate ATCC 6258 assessed as log reduction in bacterial count at MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID570829 | Antifungal activity against Candida albicans isolate 1 assessed as time period for bacterial growth inhibition at 16 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID575118 | Antifungal activity against Madurella mycetomatis isolate 68 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID559882 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 99% fungal growth reduction at 8 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID351870 | Antifungal activity against Aspergillus fumigatus expressing fks1 gene EMFR-S678P mutant after 24 to 48 hrs by broth dilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. |
| AID433455 | Ratio of AUC (0 to 24 hrs) in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.95 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID535404 | Antifungal activity against Candida albicans SC5314 expressing wild type FKS1 after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID432484 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as suppression of fungal regrowth at 5 mg/kg, ip administered 2 hrs postinfection as single dose by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531342 | Antimicrobial activity against Candida glabrata isolate 7754 after 48 hrs by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. |
| AID374506 | Antifungal activity against Candida tropicalis isolate 0050-028 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID535405 | Antifungal activity against Candida albicans 4715 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID555571 | Antimicrobial activity against Candida guilliermondii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID574113 | Fungicidal activity against Candida albicans isolate 1 assessed as log reduction in bacterial count at 16 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID521316 | Antimicrobial activity against Aspergillus terreus hyphae isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID323314 | Antifungal activity against Candida dubliniensis FS after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID544173 | Inhibition of Candida albicans A15-10 1,3-beta-D-glucan synthase subunit FKS1p T1933C mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID323300 | Antifungal activity against Candida dubliniensis 75/043 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID574114 | Fungicidal activity against Candida albicans isolate 1 assessed as log reduction in bacterial count at 4 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432248 | Ratio of log2 of MEC for germinated Aspergillus terreus to log2 of MEC for nongerminated Aspergillus terreus | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID522730 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 16 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID372839 | Antifungal activity against Aspergillus flavus isolate 0001-061 after 24 hrs by CLSI M38-A broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID518784 | Antifungal activity against Candida tropicalis isolate 4780 expressing fks1 F641S mutant after 24 to 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. |
| AID522712 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as mild induction of fungal death at 0.03 to 32 mg/L after 6 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID324314 | Ratio of MIC for Candida glabrata to MIC for Candida glabrata in presence of 50% mouse serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID432658 | Ratio of Cmax in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 6.8 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID520619 | Antifungal activity against Candida orthopsilosis by microdilution AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. |
| AID433676 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.95 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-17 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531139 | Antifungal activity against Candida orthopsilosis H10 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID555584 | Antimicrobial activity against Candida zeylanoides by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID374499 | Ratio of MIC50 for Candida parapsilosis isolate 0036-030 in presence of 50% human serum to MIC50 for Candida parapsilosis isolate 0036-030 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID531153 | Inhibition of Candida parapsilosis H4 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID509668 | Antimicrobial activity against Pichia guilliermondii ATCC 6260 after 24 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID570881 | Antifungal activity against Candida krusei isolate 1 assessed as cell wall damage at MIC by Transmission electron microscopy | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID544160 | Inhibition of Candida albicans 119 1,3-beta-D-glucan synthase subunit FKS1p T1921C mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID565367 | Antifungal activity against Candida dubliniensis 10035 after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID531234 | Antifungal activity against Candida albicans after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID518788 | Antifungal activity against Candida glabrata isolate 4720 expressing fks2 S645P mutant after 24 to 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. |
| AID432647 | Ratio of Cmax in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.15 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID546075 | Antifungal activity against Candida guilliermondii isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID433028 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID564253 | Total body clearance in healthy human at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID565365 | Antifungal activity against Candida dubliniensis 10034 after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID432272 | Increase in metabolic activity of nongerminated Aspergillus flavus assessed as formation of short, stubby aberrant hyphae at 0.03 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID544410 | Selectivity ratio of Ki for Candida albicans 5415 1,3-beta-D-glucan synthase subunit FKS1p T1933C mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID574341 | Fungicidal activity against Candida krusei isolate ATCC 6258 assessed as log reduction in bacterial count at 16 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID574342 | Fungicidal activity against Candida krusei isolate ATCC 6258 assessed as log reduction in bacterial count at 4 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522757 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 0.25 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID546068 | Antifungal activity against Candida albicans isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID323361 | Antifungal activity against Candida glabrata 05-761 isolate assessed as decrease in fungal turbidity by microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID564449 | Drug level healthy human alveolar macrophage at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions after 12 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID432505 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 3.90 +/- 0.15 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days mea | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433659 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 3.72 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID559865 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 90% fungal growth reduction at 0.5 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID432509 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 48 hrs up to 4 days measured per 96 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID545195 | Antimicrobial activity against Candida albicans isolate R at 25 ug/ml grown on RPMI 1640 medium after 24 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID323312 | Antifungal activity against Candida dubliniensis B71507 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID574117 | Fungicidal activity against Candida albicans isolate 2 assessed as log reduction in bacterial count at 4 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID324321 | Inhibition of glucan synthase in Candida albicans 36082 assessed as incorporation of [3H]uridine diphosphoglucose in presence of 50% serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID374513 | Antifungal activity against Aspergillus niger isolate 0001-073 after 24 hrs by CLSI M38-A broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID555592 | Antimicrobial activity against Trichosporon inkin by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID570834 | Antifungal activity against Candida glabrata isolate 3 assessed as time period for bacterial growth inhibition at 16 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432278 | Increase in metabolic activity of nongerminated Aspergillus flavus assessed as elongation of short, stubby aberrant hyphae at 2 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID522729 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 4 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID531160 | Inhibition of Saccharomyces cerevisiae BY4742-FKS1P649A mutant glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID432273 | Increase in metabolic activity of germinated Aspergillus flavus assessed as formation of short, stubby aberrant hyphae at 0.03 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID570877 | Increase in susceptibility to calcofluor white in Candida krusei isolate ATCC 6258 assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID516196 | Antifungal activity against Candida parapsilosis 20557.012 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID582581 | Inhibition of Candida glabrata isolate 21900 1,3-beta-D-glucan synthase Fks1p D632G mutant/wild type Fks2p | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID576545 | Antimicrobial activity against Candida albicans SC5314 assessed as reduction of biofilm metabolic activity in in vitro catheter-associated rat model by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis. |
| AID555590 | Antimicrobial activity against Trichosporon asahii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID509669 | Antimicrobial activity against Candida famata after 24 hrs by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID323329 | Antifungal activity against Candida dubliniensis SCS17154969-2 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID324346 | Inhibition of glucan synthase in Candida albicans SC5314 in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID544188 | Activity at Candida albicans 122 1,3-beta-D-glucan synthase subunit FKS1p C1946A mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID544184 | Activity at Candida albicans 5415 1,3-beta-D-glucan synthase subunit FKS1p T1933C mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID574328 | Fungicidal activity against Candida parapsilosis isolate 1 assessed as log reduction in bacterial count at 16 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433053 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 2.45 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 513 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID565372 | Antifungal activity against Candida dubliniensis 10033 by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID544151 | Antimicrobial activity against Candida albicans A15 harboring FKS1 T1933Y mutant gene and FKS1 hotspot1 S645S/P mutant gene by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID546074 | Antifungal activity against Candida dubliniensis isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID575123 | Inhibition of beta-1,3-D-glucan synthesis in Aspergillus fumigatus ATCC 204305 after 48 hrs by alanine blue assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID531151 | Antifungal activity against Candida glabrata T51916 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID555599 | Antimicrobial activity against Cryptococcus laurentii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID544153 | Antimicrobial activity against Candida albicans A15-10 harboring FKS1 T1933C mutant gene and FKS1 hotspot1 S645P mutant by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID433618 | Antifungal activity against Candida albicans 98-210 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID545282 | Antimicrobial activity against Candida albicans isolate S at 25 ug/ml grown on RPMI 1640 medium after 48 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID516178 | Antifungal activity against Candida glabrata 33609 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID522732 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 0.25 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID555595 | Antimicrobial activity against Trichosporon jirovecii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID570884 | Antifungal activity against Candida glabrata isolate 1 assessed as cell wall damage at 4 times MIC by Transmission electron microscopy | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433249 | Ratio of Cmax in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 7.5 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID516184 | Antifungal activity against Candida glabrata 37661 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID559662 | Fungicidal activity against Candida krusei CY118 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID544137 | Antimicrobial activity against Candida albicans 89 harboring FKS1 C1934A mutant gene and FKS1 hotspot1 S645Y mutant gene by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID432841 | Ratio of free-drug Cmax in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 1.25 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans K-20 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID535419 | Antifungal activity against Candida albicans 2762 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method in presence of 50% human serum | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID433629 | Antifungal activity against Candida glabrata 5376 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID545192 | Antimicrobial activity against Candida albicans isolate S infected in NMRI mouse assessed as decrease in kidney bacterial burden at 12 mg/kg, ip measured on day 4 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID516190 | Antifungal activity against Candida parapsilosis 20423.072 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID323269 | Antifungal activity against Candida albicans B06-341 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID521315 | Antimicrobial activity against Aspergillus fumigatus hyphae isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID554486 | Antifungal activity against Aspergillus fumigatus Af293 assessed as abnormal hyphal growth by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. |
| AID518079 | Ratio of AUC (0 to 24 hrs) in Candida parapsilosis infected neutropenic ICR Swiss mouse to MIC for Candida parapsilosis at 1 log kill dose after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID432500 | Fraction unbound in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse serum at 20 mg/kg, ip administered 2 hrs postinfection as single dose measured after 32 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374520 | Ratio of MIC50 for Aspergillus fumigatus isolate 00020-018 in presence of 50% human serum to MIC50 for Aspergillus fumigatus isolate 0020-018 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID574091 | Antifungal activity against Candida tropicalis by NCCLS M27A broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID326112 | Paradoxical effect in Candida albicans assessed as increase in turbidity at 16 times MIC | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. |
| AID433237 | Antifungal activity against Candida glabrata 32930 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433412 | Ratio of Cmax in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 11.8 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433215 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 3.57 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5592 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323324 | Antifungal activity against Candida dubliniensis Leic875 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID432855 | Ratio of free-drug Cmax in Candida albicans 98-207-infected neutropenic ICR/Swiss mouse candidiasis model at 1.15 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-207 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374476 | Antifungal activity against Candida krusei isolate 0001-058 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID518785 | Antifungal activity against Candida glabrata isolate 4708 expressing fks1 S645P mutant after 24 to 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. |
| AID509641 | Antimicrobial activity against caspofungin-resistant Candida albicans T26 by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID545149 | Antimicrobial activity against Candida albicans isolate R after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID574329 | Fungicidal activity against Candida parapsilosis isolate 1 assessed as log reduction in bacterial count at 4 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID509657 | Antimicrobial activity against Candida albicans after 24 hrs CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID518078 | Ratio of AUC (0 to 24 hrs) in Candida glabrata infected neutropenic ICR Swiss mouse to MIC for Candida glabrata at 1 log kill dose after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID570865 | Increase in susceptibility to calcofluor white in Candida albicans ATCC 90028 assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID574315 | Fungicidal activity against Candida albicans isolate S assessed as log reduction in bacterial count at 16 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433622 | Antifungal activity against Candida glabrata 513 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323337 | Antifungal activity against Candida dubliniensis ST after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID433630 | Antifungal activity against Candida glabrata 37661 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID509646 | Antimicrobial activity against caspofungin-resistant Candida albicans CAI4 by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID544168 | Inhibition of Candida albicans 122 1,3-beta-D-glucan synthase subunit FKS1p C1946A mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID529561 | Antimicrobial activity against Candida albicans grown as planktonic cell by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | In vitro activity of anidulafungin against Candida albicans biofilms. |
| AID534350 | Antifungal activity against fsk1 gene deficient Candida albicans | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. |
| AID535424 | Antifungal activity against Candida albicans 43001 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method in presence of 50% human serum | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID432263 | Induction of maximal metabolic inhibition in germinated Aspergillus fumigatus assessed as minimal metabolic activity Ymin after 2 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID433039 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 1.97 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544408 | Selectivity ratio of Ki for Candida albicans 2762 1,3-beta-D-glucan synthase subunit FKS1p T1922C mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID432268 | Increase in metabolic activity of nongerminated Aspergillus fumigatus assessed as formation of short, stubby aberrant hyphae at 0.03 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID582574 | Antifungal activity against Candida glabrata isolate 51916 expressing wild type Fks1p and Fks2p P667T mutant by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID531162 | Inhibition of Candida albicans Sc5314 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID570880 | Antifungal activity against Candida glabrata isolate 1 assessed as cell wall damage at MIC by Transmission electron microscopy | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID555615 | Antimicrobial activity against Aspergillus spp. by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID535410 | Antifungal activity against Candida albicans 41509 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID525543 | Antimicrobial activity against Fonsecaea monophora isolates after 72 hrs by CLSI M38-A2 protocol method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. |
| AID433223 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 2.45 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 513 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID326107 | Antifungal activity against Candida tropicalis after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. |
| AID433222 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 1.97 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 570 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544185 | Activity at Candida albicans 89 1,3-beta-D-glucan synthase subunit FKS1p C1934A mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID575104 | Antifungal activity against Madurella mycetomatis isolate 31 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID324336 | Inhibition of glucan synthase in Candida albicans ATCC 90028 in presence of 10% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID535421 | Antifungal activity against Candida albicans 4254 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method in presence of 50% human serum | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID521311 | Antimicrobial activity against Aspergillus fumigatus conidia isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method in presence of voriconazole | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID432661 | Ratio of Cmax in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 3.37 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID545164 | Antimicrobial activity against Candida albicans isolate R at 0.125 ug/ml after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID544169 | Inhibition of Candida albicans 121 1,3-beta-D-glucan synthase subunit FKS1p G4082A mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID531136 | Antifungal activity against Candida parapsilosis ATCC 22019 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID544314 | Inhibition of human CYP2C8 using rosiglitazone as a substrate | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID544176 | Activity at Candida albicans 90028 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID509666 | Antimicrobial activity against Issatchenkia orientalis after 24 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID582567 | Antifungal activity against Candida glabrata isolate 42971 expressing Fks1p D632Y mutant and Fks2p R1377STOP mutant by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID433621 | Antifungal activity against Candida glabrata 570 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432410 | Antifungal activity against germinated Aspergillus fumigatus assessed as absence of visual fungal growth at 128 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID433214 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 35315-infected neutropenic ICR/Swiss mouse candidiasis model at 6.4 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 35315 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574089 | Antifungal activity against Candida parapsilosis by NCCLS M27A broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID324341 | Inhibition of glucan synthase in Candida albicans ATCC 36082 in presence of 20% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID559647 | Fungicidal activity against Candida krusei ATCC 6258 bloodstream forms after 48 hrs by M27-A3 microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID432327 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as reduction of viral burden in kidney at 1.25 mg/kg, ip administered 2 hrs postinfection as single dose measured after 96 hrs post dosing | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544181 | Activity at Candida albicans 177 1,3-beta-D-glucan synthase subunit FKS1p T1922C mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID570854 | Increase in susceptibility to SDS in Candida glabrata isolate 1 assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID374527 | Antifungal activity against Aspergillus flavus isolate 0001-033 after 24 hrs by CLSI M38-A broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID324322 | Antifungal activity against Candida albicans 36082 infected BALB/c mouse assessed as fungal kidney burden after 14 days | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID324335 | Inhibition of glucan synthase in Candida albicans ATCC 90028 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID574316 | Fungicidal activity against Candida albicans isolate S assessed as log reduction in bacterial count at 4 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID554487 | Antifungal activity against cnaA deficient Aspergillus fumigatus Af293 assessed as abnormal hyphal growth by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. |
| AID432250 | Antifungal activity against germinated Aspergillus flavus assessed as lowest drug concentration that produced short, stubby and highly branched hyphae after 48 hrs by microscopic analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID522766 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 32 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID433245 | Ratio of Cmax in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 4.13 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID535425 | Antifungal activity against Candida albicans 42996 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method in presence of 50% human serum | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID522755 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 16 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID574312 | Fungicidal activity against Candida krusei isolate 1 assessed as log reduction in bacterial count at 16 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432476 | Drug level in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse serum at 20 mg/kg, ip administered 2 hrs postinfection as single dose measured after 32 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374488 | Ratio of MIC50 for Candida lusitaniae isolate 0015-049 in presence of 50% human serum to MIC50 for Candida lusitaniae isolate 0015-049 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID432329 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as reduction of viral burden in kidney at 5 mg/kg, ip administered 2 hrs postinfection as single dose measured after 96 hrs post dosing by | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544128 | Antimicrobial activity against Candida albicans 177 harboring FKS1 T1922C mutant gene and FKS1 hotspot1 F641S mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID432309 | Antifungal activity against Candida glabrata 35315 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID582566 | Antifungal activity against Candida glabrata isolate 3169 expressing Fks1p D632E mutant and wild type Fks2p by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID545209 | Antimicrobial activity against Candida albicans isolate S at 5 ug/ml grown on Muller-Hinton agar medium after 24 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID374522 | Antifungal activity against Aspergillus fumigatus isolate 0002-020 after 24 hrs by CLSI M38-A broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID531343 | Antimicrobial activity against Candida glabrata isolate 7755 FKS2 F659V mutant gene after 48 hrs by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. |
| AID555797 | Antimicrobial activity against Alternaria alternata by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID432666 | Ratio of Cmax in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531141 | Antifungal activity against Candida metapsilosis am-2006-0113 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID555574 | Antimicrobial activity against Candida rugosa by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID432308 | Antifungal activity against Candida glabrata 34341 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433248 | Ratio of Cmax in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 11.8 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433692 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 3.31 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 32930 aft | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544154 | Inhibition of Candida albicans SC5314 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID574348 | Antifungal activity against Candida albicans ATCC 90028 assessed as time period for bacterial growth inhibition at 4 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID518086 | Antifungal activity against Candida albicans infected in ICR Swiss mouse assessed as log reduction in bacterial count after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID433627 | Antifungal activity against Candida glabrata 35315 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432475 | Drug level in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse serum at 5 mg/kg, ip administered 2 hrs postinfection as single dose | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432504 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per 96 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555587 | Antimicrobial activity against Yarrowia lipolytica by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID374508 | Ratio of MIC50 for Candida tropicalis isolate 0050-028 in presence of 50% human serum to MIC50 for Candida tropicalis isolate 0050-028 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID570845 | Increase in susceptibility to SDS in Candida parapsilosis isolate A assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID323355 | Antifungal activity against Candida glabrata 05-62 isolate in presence of 5% human serum after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID518067 | Half life in Candida albicans infected neutropenic ICR Swiss mouse at 80 mg/kg, ip | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID516181 | Antifungal activity against Candida glabrata 35315 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID432320 | AUC (0 to infinity) in serum of neutropenic ICR/Swiss mouse candidiasis model at 5 mg/kg, ip by reverse-phase high-pressure liquid chromatography | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522774 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 4 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID518081 | Ratio of fAUC (0 to 24 hrs) in Candida glabrata infected neutropenic ICR Swiss mouse to MIC for Candida glabrata at 1 log kill dose after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID535631 | Inhibition of Candida albicans 205 glucan synthase subunit FKS1p FLTLPLRDP mutant at monophasic kinetics | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID559030 | Plasma concentration in mouse infected with Candida albicans at 10 mg/kg, ip after 3 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID531154 | Inhibition of Candida parapsilosis H5 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID574330 | Fungicidal activity against Candida parapsilosis isolate 1 assessed as log reduction in bacterial count at MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID374477 | Ratio of MIC50 for Candida krusei isolate 0001-058 in presence of 50% human serum to MIC50 for Candida krusei isolate 0001-058 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID433204 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 1.25 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans K-1 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID509640 | Antimicrobial activity against caspofungin-resistant Candida albicans T25 by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID544177 | Activity at Candida albicans 1002 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID549034 | Antimicrobial activity against Candida krusei LMR 39-14 infected in immunosuppressed CF-1 mouse assessed as increased survival of mouse at 10 mg/kg, ip administered once daily for 5 days relative to control | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. |
| AID555602 | Antimicrobial activity against Trichosporon spp. by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID432673 | Ratio of free-drug Cmax in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.15 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432821 | Ratio of free-drug Cmax in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 2.45 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323280 | Antifungal activity against Candida albicans NCPF6525 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID574317 | Fungicidal activity against Candida albicans isolate S assessed as log reduction in bacterial count at MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID323342 | Antifungal activity against Candida krusei ATCC 6258 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID509670 | Antimicrobial activity against Candida famata after 24 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID323348 | Antifungal activity against Candida glabrata 05-761 isolate after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID555579 | Antimicrobial activity against Candida intermedia by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID432279 | Increase in metabolic activity of germinated Aspergillus flavus assessed as elongation of short, stubby aberrant hyphae at 2 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID522767 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 0.25 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID544417 | Selectivity ratio of Ki for Candida albicans 90 1,3-beta-D-glucan synthase subunit FKS1p G4082R mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID559893 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as minimum concentration producing >= 100% growth reduction after 48 hrs by M27-A3 microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID531167 | Inhibition of Candida glabrata T51916 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID559024 | Plasma concentration in mouse infected with Candida albicans at 5 mg/kg, ip after 1 hr | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID324317 | Ratio of MIC for Candida tropicalis to MIC for Candida tropicalis in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID432301 | Antifungal activity against Candida albicans 580 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544412 | Selectivity ratio of Ki for Candida albicans 85 1,3-beta-D-glucan synthase subunit FKS1p C1934T mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID564264 | Drug level healthy human plasma at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions after 4 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID522690 | Fungicidal activity against Candida orthopsilosis isolate CP-150 bloodstream form by CLSI method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID432274 | Increase in metabolic activity of nongerminated Aspergillus fumigatus assessed as elongation of short, stubby aberrant hyphae at 2 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID531152 | Inhibition of Candida parapsilosis ATCC 22019 glucan synthase by assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID531344 | Antimicrobial activity against Candida glabrata isolate 7754 after 48 hrs by broth dilution method in presence of 50% of human serum | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. |
| AID433062 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 3.37 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-210 aft | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432847 | Ratio of free-drug Cmax in Candida glabrata 5203-infected neutropenic ICR/Swiss mouse candidiasis model at 2.45 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5203 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555631 | Antimicrobial activity against Chrysonilia sitophila by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID555629 | Antimicrobial activity against Fusarium reticulatum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID374494 | Antifungal activity against Candida parapsilosis isolate 0026-003 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID531165 | Inhibition of Candida albicans M122 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID543920 | Antimicrobial activity against Candida albicans 90028 by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID432642 | Antifungal activity against Candida glabrata 34341 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 1.83 +/- 0.54 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days m | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531164 | Inhibition of Candida albicans ATCC 36082 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID323278 | Antifungal activity against Candida albicans JIMS146204 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID425792 | Antifungal activity against Candida albicans GDH2346 grown as biofilm assessed as 50% reduction in metabolic activity of biofilm after 24 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID432249 | Antifungal activity against nongerminated Aspergillus flavus assessed as lowest drug concentration that produced short, stubby and highly branched hyphae after 48 hrs by microscopic analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID323294 | Antifungal activity against Candida albicans T25 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID324330 | Inhibition of glucan synthase in Aspergillus fumigatus MF5668 in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID555570 | Antimicrobial activity against Candida krusei by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID546070 | Antifungal activity against Candida parapsilosis isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID565382 | Antifungal activity against Candida dubliniensis 9456 assessed as compound concentration at which paradoxical growth of observed after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID433063 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 0.94 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans 580 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544165 | Inhibition of Candida albicans 89 1,3-beta-D-glucan synthase subunit FKS1p C1934A mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID374486 | Antifungal activity against Candida lusitaniae isolate 0015-049 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID425800 | Antifungal activity against Candida parapsilosis PA/71 grown as biofilm assessed as 50% reduction in metabolic activity of biofilm after 24 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID555582 | Antimicrobial activity against Candida orthopsilosis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID432662 | Ratio of Cmax in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 0.94 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574332 | Fungicidal activity against Candida parapsilosis isolate S assessed as log reduction in bacterial count at 4 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433448 | Ratio of free-drug Cmax in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 3.72 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555609 | Antimicrobial activity against Aspergillus versicolor by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID432864 | Ratio of free-drug Cmax in Candida glabrata 353205-infected neutropenic ICR/Swiss mouse candidiasis model at 6.4 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 353205 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555803 | Antimicrobial activity against Cladophialophora bantiana by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID570878 | Antifungal activity against Candida albicans isolate 1 assessed as cell wall damage at MIC by Transmission electron microscopy | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID555608 | Antimicrobial activity against Aspergillus sydowii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID574116 | Fungicidal activity against Candida albicans isolate 2 assessed as log reduction in bacterial count at 16 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433411 | Ratio of Cmax in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 3.31 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323275 | Antifungal activity against Candida albicans JIMS132203 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID518088 | Antifungal activity against Candida parapsilosis infected in ICR Swiss mouse assessed log reduction in bacterial count after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID374481 | Antifungal activity against Candida krusei ATCC 6258 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID433418 | Ratio of free-drug Cmax in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 3.72 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522764 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 4 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID555577 | Antimicrobial activity against Candida coliculosa by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID323288 | Antifungal activity against Candida albicans NR3 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID574307 | Fungicidal activity against Candida glabrata isolate 3 assessed as log reduction in bacterial count at 4 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID323261 | Antifungal activity against Candida albicans SCS140136P after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID529560 | Antimicrobial activity against Candida albicans grown as planktonic cell after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | In vitro activity of anidulafungin against Candida albicans biofilms. |
| AID433228 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 3.57 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5592 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570839 | Increase in susceptibility to SDS in Candida parapsilosis isolate 1 assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID574308 | Fungicidal activity against Candida glabrata isolate 3 assessed as log reduction in bacterial count at MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID323316 | Antifungal activity against Candida dubliniensis IK after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID529568 | Volume of distribution in F344 rat at 5 mg/kg, iv administered as single bolus dose | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Pharmacokinetics and tissue distribution of anidulafungin in rats. |
| AID570846 | Increase in susceptibility to SDS in Candida parapsilosis isolate 1 assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID323303 | Antifungal activity against Candida dubliniensis 90/033 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID555627 | Antimicrobial activity against Hormographiella aspergillata by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID535618 | Antifungal activity against Candida tropicalis T3 blood stream isolate harboring Fks1p FLTLS/PLRDP mutant protein | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID432302 | Antifungal activity against Candida tropicalis 98-234 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555597 | Antimicrobial activity against Ustilago spp by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID432830 | Ratio of free-drug Cmax in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 3.37 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522709 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as induction of fungal killing rate at 0.03 to 32 mg/L measured at 6 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID323317 | Antifungal activity against Candida dubliniensis J930936 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID555601 | Antimicrobial activity against Trichosporon mycotoxinivorans by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID535628 | Inhibition of Candida tropicalis T19 blood stream isolate glucan synthase subunit FKS1p with FLTLS/PLRDP mutant at biphasic kinetics | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID432633 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 3.81 +/- 0.33 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days mea | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544317 | Inhibition of human CYP2D6 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID433650 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 4.13 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432674 | Ratio of free-drug Cmax in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 3.37 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433038 | Ratio of AUC (0 to 24 hrs) in Candida tropicalis 98-234-infected neutropenic ICR/Swiss mouse candidiasis model at 3.81 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida tropicalis 98-234 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432488 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as suppression of fungal regrowth at 1.25 mg/kg, ip administered 2 hrs postinfection as single dose by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574129 | Fungicidal activity against Candida glabrata isolate 1 assessed as log reduction in bacterial count at 4 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID565388 | Antifungal activity against Candida dubliniensis FMR 10032 infected in OF1 mouse assessed as fungal count in kidney at 1 mg/kg/day, iv after 24 hrs by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID574106 | Antifungal activity against Candida krusei isolate 1 by CLSI M27-A3 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID549035 | Antimicrobial activity against Candida krusei LMR 39-14 infected in immunosuppressed CF-1 mouse assessed as increased survival of mouse at 20 mg/kg, ip administered once daily for 5 days relative to control | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. |
| AID545167 | Antimicrobial activity against Candida albicans isolate C after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID433436 | Ratio of free-drug Cmax in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 13 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID554492 | Antifungal activity against rasA deficient Aspergillus fumigatus H237 assessed as abnormal hyphal growth by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. |
| AID433634 | Antifungal activity against Candida albicans 580 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374510 | Antifungal activity against Aspergillus terreus isolate 0031-087 after 48 hrs by CLSI M38-A broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID543922 | Antimicrobial activity against Candida albicans 1002 by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID555589 | Antimicrobial activity against Cryptococcus neoformans var. neoformans by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID323350 | Antifungal activity against Candida glabrata 05-761 isolate in presence of 50% mouse serum after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID582552 | Antifungal activity against Candida glabrata isolate 31498 expressing wild type Fks1p and Fks2p F659 deletion mutant by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID374525 | Antifungal activity against Aspergillus fumigatus isolate 0002-021 after 24 hrs by CLSI M38-A broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID518072 | Ratio of AUC (0 to 24 hrs) in Candida glabrata infected neutropenic ICR Swiss mouse to MIC for Candida glabrata at static dose after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID433068 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 1.58 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 32930 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433040 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 2.45 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544157 | Inhibition of Candida albicans 1002 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID522798 | Inhibition of Candida glabrata CG-C3 FKS2 T1987C mutant | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID323358 | Antifungal activity against Candida glabrata 05-761 isolate infected ICR mouse kidney assessed as reduction of tissue fungal burden at 0.5 mg/kg, ip | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID433250 | Ratio of Cmax in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432831 | Ratio of free-drug Cmax in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 0.94 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544191 | Activity at Candida albicans 90 1,3-beta-D-glucan synthase subunit FKS1p G4082R mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID582551 | Antifungal activity against Candida glabrata isolate 42971 expressing Fks1p D632Y mutant and Fks2p R1377STOP mutant by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID433024 | Ratio of AUC (0 to 24 hrs) in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 0.94 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID565380 | Antifungal activity against Candida dubliniensis FMR 10032 infected in immunosuppressed OF1 mouse assessed as fungal count in kidney at 1 mg/kg/day, iv after 24 hrs by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID565369 | Antifungal activity against Candida dubliniensis 9456 by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID546072 | Antifungal activity against Candida glabrata isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID574096 | Antifungal activity against Candida albicans ATCC 90028 by CLSI M27-A3 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID555604 | Antimicrobial activity against Aspergillus terreus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID531239 | Antifungal activity against Candida lusitaniae after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID555613 | Antimicrobial activity against Aspergillus sclerotiorum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID570875 | Increase in susceptibility to calcofluor white in Candida glabrata isolate 1 assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433694 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 7.5 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5376 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555614 | Antimicrobial activity against Aspergillus glaucus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID582592 | Ratio of IC50 for Candida glabrata wild type 1,3-beta-glucan synthase to IC50 for Candida glabrata 1,3-beta-glucan synthase mutant | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID520618 | Antifungal activity against Candida parapsilosis by microdilution AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. |
| AID509665 | Antimicrobial activity against Issatchenkia orientalis after 24 hrs by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID545172 | Antimicrobial activity against Candida albicans isolate C at 0.125 ug/ml after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID545165 | Antimicrobial activity against Candida albicans isolate C after 48 hrs by EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID433227 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 35315-infected neutropenic ICR/Swiss mouse candidiasis model at 6.4 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 35315 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433865 | Ratio of antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model at 320 mg/kg, ip administered every 16 hrs up to 4 days to at 1.25 mg/kg, ip administered every 16 hrs up to 4 days | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID324333 | Inhibition of glucan synthase in Aspergillus fumigatus ATCC 13073 in presence of 20% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID433670 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 4.13 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 513 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522718 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as induction of maximal fungal death at 8 mg/L after 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID432253 | Effect on nongerminated Aspergillus fumigatus metabolic activity assessed as drug concentration at which fungal metabolic activity occurs after 2 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID555598 | Antimicrobial activity against Rhodotorula glutinis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID509658 | Antimicrobial activity against Candida albicans after 24 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID433652 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 3.31 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531340 | Antimicrobial activity against Candida glabrata isolate 7754 after 24 hrs by broth dilution method in presence of 50% of human serum | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. |
| AID555572 | Antimicrobial activity against Candida lusitaniae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID574132 | Fungicidal activity against Candida glabrata isolate 2 assessed as log reduction in bacterial count at 4 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID575115 | Antifungal activity against Madurella mycetomatis isolate 54 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID522736 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 32 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID432477 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as reduction of viral burden in kidney at 20 mg/kg, ip administered 2 hrs postinfection as single dose measured within 1 to 4 hrs post dosi | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID565075 | Antimicrobial activity against Blastoschizomyces capitatus by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Case of fatal Blastoschizomyces capitatus infection occurring in a patient receiving empiric micafungin therapy. |
| AID432494 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as prolongation of fungal growth suppression at 1.25 mg/kg, ip administered 2 hrs postinfection as single dose by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID565354 | Antifungal activity against Candida dubliniensis 9453 after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID518074 | Ratio of fAUC (0 to 24 hrs) in Candida albicans infected neutropenic ICR Swiss mouse to MIC for Candida albicans at static dose after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID433433 | Ratio of free-drug Cmax in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 7.5 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432280 | Increase in metabolic activity of nongerminated Aspergillus fumigatus elongation of short, stubby aberrant hyphae at 16 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID574115 | Fungicidal activity against Candida albicans isolate 1 assessed as log reduction in bacterial count at MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432496 | Fraction unbound in Candida albicans K-1 infected neutropenic ICR/Swiss mouse serum at 5 mg/kg, ip administered 2 hrs postinfection as single dose | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433678 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 2.31 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans 580 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433413 | Ratio of Cmax in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 7.5 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID582564 | Antifungal activity against Candida glabrata isolate 5847 expressing Fks1p S629P mutant and wild type Fks2p by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID432641 | Antifungal activity against Candida glabrata 32930 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 1.83 +/- 0.54 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days m | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433450 | Ratio of free-drug Cmax in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 4.21 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID535623 | Inhibition of Candida tropicalis ATCC 750 glucan synthase subunit FKS1p at monophasic kinetics | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID324339 | Inhibition of glucan synthase in Candida albicans ATCC 36082 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID522791 | Antifungal activity against wild type Candida albicans ATCC 90028 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID559648 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as minimum concentration producing >= 50% growth reduction after 24 hrs by M27-A3 microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID374347 | Antifungal activity against Candida krusei isolate 0001-058 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID323339 | Antifungal activity against Candida parapsilosis ATCC 22019 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID433857 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 7.5 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5376 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574094 | Antifungal activity against Candida guilliermondii by NCCLS M27A broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433205 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.15 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-17 aft | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323298 | Antifungal activity against Candida albicans Y109 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID555801 | Antimicrobial activity against Hortaea werneckii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID559655 | Antifungal activity against Candida krusei CK18 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID374335 | Antifungal activity against Candida albicans isolate 0012-025 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID518091 | Antifungal activity against Candida parapsilosis infected in ICR Swiss mouse | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID522743 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 1 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID545163 | Antimicrobial activity against Candida albicans isolate R at 0.003 ug/ml after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID544150 | Antimicrobial activity against Candida albicans A15 harboring FKS1 T1933Y mutant gene and FKS1 hotspot1 S645S/P mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID323302 | Antifungal activity against Candida dubliniensis 81/060 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID516191 | Antifungal activity against Candida parapsilosis 20423.078 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID432306 | Antifungal activity against Candida glabrata 32930 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432256 | Effect on nongerminated Aspergillus terreus metabolic activity assessed as drug concentration at which fungal metabolic activity occurs after 2 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID432326 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as reduction of viral burden in kidney at 5 mg/kg, ip administered 2 hrs postinfection as single dose measured after 96 hrs post dosing by | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432507 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as viral burden per kidney administered intraperitoneally every 48 hrs up to 4 days measured per 96 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID546079 | Antifungal activity against Candida lipolytica isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID433863 | Plasma protein binding in patient with serious fungal disease by equilibrium dialysis | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555569 | Antimicrobial activity against Candida glabrata by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID509661 | Antimicrobial activity against Candida tropicalis after 24 hrs by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID323372 | Antifungal activity against Candida glabrata 05-62 isolate after 22 hrs by XTT assay | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID574108 | Fungicidal activity against Candida albicans isolate S assessed as log reduction in bacterial count at 4 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522781 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 32 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID555567 | Antimicrobial activity against Candida parapsilosis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID432276 | Increase in metabolic activity of nongerminated Aspergillus terreus assessed as elongation of short, stubby aberrant hyphae at 2 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID575121 | Antifungal activity against Aspergillus fumigatus ATCC 204305 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID582486 | Antifungal activity against Candida glabrata isolate 218 expressing wild type Fks1p and Fks2p by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID323351 | Antifungal activity against Candida glabrata 05-761 isolate in presence of 5% human serum after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID432478 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as reduction of viral burden in kidney at 5 mg/kg, ip administered 2 hrs postinfection as single dose measured within 1 to 4 hrs post dosin | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432257 | Effect on germinated Aspergillus terreus metabolic activity assessed as drug concentration at which fungal metabolic activity occurs after 2 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID571046 | Inhibition of Candida parapsilosis isolate A adherence to human buccal epithelial cells at 4 times MIC after 1 hr by adherence assay relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID509659 | Antimicrobial activity against Candida parapsilosis after 24 hrs by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID544161 | Inhibition of Candida albicans 177 1,3-beta-D-glucan synthase subunit FKS1p T1922C mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID545171 | Antimicrobial activity against Candida albicans isolate C at 0.003 ug/ml after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID570864 | Increase in susceptibility to calcofluor white in Candida albicans isolate 1 assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID535620 | Antifungal activity against Candida tropicalis T26 blood stream isolate harboring Fks1p LLTLSLRDP mutant protein | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID559646 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as minimum concentration producing >= 100% growth reduction after 24 hrs by M27-A3 microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID546083 | Antifungal activity against Candida parapsilosis ATCC 22019 isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID546069 | Antifungal activity against Candida krusei isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID549030 | Antimicrobial activity against Candida krusei LMR 39-14 infected in immunosuppressed CF-1 mouse assessed as serum 1,3-beta-D-glucan level at 10 mg/kg, ip administered once daily for 5 days measured after 10 days (Rvb= 5.22) | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. |
| AID574313 | Fungicidal activity against Candida krusei isolate 1 assessed as log reduction in bacterial count at 4 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID545202 | Antimicrobial activity against Candida albicans isolate R at 1 ug/ml grown on Muller-Hinton agar medium after 48 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID555617 | Antimicrobial activity against Fusarium solani by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID559875 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 99.9% fungal growth reduction at 2 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID544166 | Inhibition of Candida albicans 85 1,3-beta-D-glucan synthase subunit FKS1p C1934T mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID559659 | Antifungal activity against Candida krusei EU220 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID529544 | Antifungal activity against Candida glabrata 06-3168 obtained from patient on compound therapy by M27-A2 method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. |
| AID582588 | Inhibition of Candida glabrata isolate 41400 1,3-beta-D-glucan synthase wild type Fks1p/Fks2p D666G mutant | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID432659 | Ratio of Cmax in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 1.25 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432850 | Ratio of free-drug Cmax in Candida glabrata 343420-infected neutropenic ICR/Swiss mouse candidiasis model at 6.9 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 343420 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID326106 | Antifungal activity against Candida parapsilosis after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. |
| AID433454 | Ratio of AUC (0 to 24 hrs) in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433655 | Ratio of AUC (0 to 24 hrs) in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID324328 | Inhibition of glucan synthase in Aspergillus fumigatus MF5668 in presence of 10% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID432283 | Increase in metabolic activity of germinated Aspergillus terreus assessed as elongation of short, stubby aberrant hyphae at 16 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID522776 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 32 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID544180 | Activity at Candida albicans 119 1,3-beta-D-glucan synthase subunit FKS1p T1921C mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID509671 | Antimicrobial activity against Clavispora lusitaniae ATCC 42720 after 24 hrs by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID323296 | Antifungal activity against Candida albicans T26 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID544134 | Antimicrobial activity against Candida albicans 5415 harboring FKS1 T1933C mutant gene and FKS1 hotspot1 S645P mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID565383 | Antifungal activity against Candida dubliniensis FMR 10034 infected in OF1 mouse assessed as fungal count in spleen at 1 mg/kg/day, iv after 24 hrs by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID549022 | Antimicrobial activity against Candida krusei LMR 39-14 infected in immunosuppressed CF-1 mouse assessed as decrease in kidney bacterial burden at 10 mg/kg, ip administered once daily for 5 days measured after 10 days (Rvb= 5.22) | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. |
| AID574323 | Fungicidal activity against Candida albicans isolate 2 assessed as log reduction in bacterial count at 4 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID575111 | Antifungal activity against Madurella mycetomatis isolate 46 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID546081 | Antifungal activity against Candida intermedia isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID559661 | Antifungal activity against Candida krusei CY118 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID544316 | Inhibition of human CYP2C19 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID565390 | Antifungal activity against Candida dubliniensis FMR 10032 infected in OF1 mouse assessed as fungal count in spleen at 1 mg/kg/day, iv after 24 hrs by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID433421 | Ratio of free-drug Cmax in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 3.31 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544170 | Inhibition of Candida albicans 194 1,3-beta-D-glucan synthase subunit FKS1p C1934T/G4082R mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID555566 | Antimicrobial activity against Candida albicans by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID433451 | Ratio of free-drug Cmax in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 3.31 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570844 | Increase in susceptibility to SDS in Candida albicans ATCC 90028 assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID544135 | Antimicrobial activity against Candida albicans 5415 harboring FKS1 T1933C mutant gene and FKS1 hotspot1 S645P mutant gene by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID565385 | Antifungal activity against Candida dubliniensis 10034 assessed as compound concentration at which paradoxical growth of observed after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID433647 | Ratio of AUC (0 to 24 hrs) in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 13 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522693 | Fungicidal activity against Candida metapsilosis isolate CP-132 bloodstream form by CLSI method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID544418 | Selectivity ratio of Ki for Candida albicans A15 1,3-beta-D-glucan synthase subunit FKS1p T1933Y mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID522710 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as induction of fungal killing rate at 0.03 to 32 mg/L measured at 6 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID522788 | Antifungal activity against wild type Candida glabrata ATCC 90030 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID574110 | Fungicidal activity against Candida albicans ATCC 90028 assessed as log reduction in bacterial count at 16 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID323371 | Antifungal activity against Candida glabrata 05-761 isolate after 22 hrs by XTT assay | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID542417 | Antimicrobial activity against Aspergillus terreus clinical isolate after 48 hrs by EUCAST test | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing. |
| AID574343 | Fungicidal activity against Candida krusei isolate ATCC 6258 assessed as log reduction in bacterial count at MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID374495 | Antifungal activity against Candida parapsilosis isolate 0026-003 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID570836 | Increase in susceptibility to SDS in Candida albicans isolate 1 assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID509647 | Antimicrobial activity against caspofungin-susceptible Issatchenkia orientalis CY-118 CLSI by M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID545205 | Antimicrobial activity against Candida albicans isolate S at 1 ug/ml grown on RPMI 1640 medium after 24 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID555581 | Antimicrobial activity against Candida metapsilosis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID433206 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 3.37 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-210 a | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433203 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 6.8 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5376 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID545281 | Antimicrobial activity against Candida albicans isolate S at 5 ug/ml grown on RPMI 1640 medium after 48 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID516170 | Antifungal activity against Candida albicans 98-17 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID433026 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 1.97 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570847 | Increase in susceptibility to SDS in Candida glabrata isolate 1 assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID374338 | Antifungal activity against Candida albicans isolate 0021-076 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID555808 | Antimicrobial activity against Mucor spp.by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID516176 | Antifungal activity against Candida glabrata 5592 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID546077 | Antifungal activity against Candida pelliculosa isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID433643 | Antifungal activity against Candida glabrata 5592 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555594 | Antimicrobial activity against Trichosporon dermatis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID324332 | Inhibition of glucan synthase in Aspergillus fumigatus ATCC 13073 in presence of 10% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID555795 | Antimicrobial activity against Scedosporium apiospermum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID555600 | Antimicrobial activity against Trichosporon domesticum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID525542 | Antimicrobial activity against Fonsecaea pedrosoi isolates after 72 hrs by CLSI M38-A2 protocol method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. |
| AID574100 | Antifungal activity against Candida parapsilosis isolate 1 by CLSI M27-A3 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID554491 | Antifungal activity against Aspergillus fumigatus H237 assessed as abnormal hyphal growth by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. |
| AID522803 | Inhibition of Candida glabrata CG-C2 wild type FKS | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID544129 | Antimicrobial activity against Candida albicans 177 harboring FKS1 T1922C mutant gene and FKS1 hotspot1 F641S mutant gene by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID565355 | Antifungal activity against Candida dubliniensis 9453 after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID582585 | Inhibition of Candida glabrata isolate 234 1,3-beta-D-glucan synthase wild type Fks1p/Fks2p F659V mutant | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID544142 | Antimicrobial activity against Candida albicans 122 harboring FKS1 C1946A mutant gene and FKS1 hotspot1 P649H mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID516189 | Antifungal activity against Candida parapsilosis 20477.048 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID433036 | Ratio of AUC (0 to 24 hrs) in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 3.37 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID565370 | Antifungal activity against Candida dubliniensis 10031 by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID433041 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522796 | Inhibition of Candida glabrata ATCC 90030 wild type FKS | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID432653 | Ratio of Cmax in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374339 | Antifungal activity against Candida albicans isolate 0021-076 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID433690 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 4.13 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 513 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432638 | Antifungal activity against Candida glabrata 570 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 1.83 +/- 0.54 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days mea | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433619 | Antifungal activity against Candida albicans 580 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522762 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 0.25 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID433047 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 1.25 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans K-1 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544189 | Activity at Candida albicans 121 1,3-beta-D-glucan synthase subunit FKS1p G4082A mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID433679 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 3.72 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 570 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID509664 | Antimicrobial activity against Candida glabrata after 24 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID545194 | Antimicrobial activity against Candida albicans isolate R at 5 ug/ml grown on RPMI 1640 medium after 24 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID559088 | Antimicrobial activity against Candida albicans clinical isolate biofilm by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of micafungin against planktonic and sessile Candida albicans isolates. |
| AID544405 | Activity at Candida albicans A15-10 1,3-beta-D-glucan synthase subunit FKS1p T1933Y mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID432858 | Ratio of free-drug Cmax in Candida tropicalis 98-234-infected neutropenic ICR/Swiss mouse candidiasis model at 3.81 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida tropicalis 98-234 after 24 hr | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323315 | Antifungal activity against Candida dubliniensis IK after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID522744 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 4 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID576547 | Antimicrobial activity against Candida albicans SC5314 biofilms infected in Sprague-Dawley rat implanted subcutaneously with catheter fragments challenged Candida cells assessed as bacterial load at 10 mg/kg, ip qd for 7 days (Rvb=2.92 +/- 0.34 log10 CFU/ | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis. |
| AID374512 | Antifungal activity against Aspergillus niger isolate 0001-073 after 24 hrs by CLSI M38-A broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID570837 | Increase in susceptibility to SDS in Candida albicans ATCC 90028 assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID324350 | Ratio of MIC for Aspergillus flavus to MIC for Aspergillus terreus in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID432264 | Induction of maximal metabolic inhibition in nongerminated Aspergillus terreus assessed as minimal metabolic activity Ymin after 2 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID425796 | Antifungal activity against Candida albicans M61 grown as biofilm assessed as maximum inhibition of biofilm metabolic activity at 0.5 mg/liter after 24 hrs by XTT assay relative to control | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID544146 | Antimicrobial activity against Candida albicans 194 harboring FKS1 C1934T/G4082R mutant gene and FKS1 hotspot1 S645F mutant gene and FKS1 hotspot2 R1361R/H mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID374340 | Ratio of MIC50 for Candida albicans isolate 0021-076 in presence of 50% human serum to MIC50 for Candida albicans isolate 0021-076 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID574123 | Fungicidal activity against Candida parapsilosis isolate 1 assessed as log reduction in bacterial count at 4 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID535622 | Antifungal activity against Candida albicans 205 harboring Fks1p FLTLPLRDP mutant protein | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID544155 | Inhibition of Candida albicans 36082 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID582579 | Inhibition of Candida glabrata isolate 42997 1,3-beta-D-glucan synthase Fks1p F625S mutant/wild type Fks2p | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID582580 | Inhibition of Candida glabrata isolate 5847 1,3-beta-D-glucan synthase Fks1p S629P mutant/wild type Fks2p | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID323295 | Antifungal activity against Candida albicans T26 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID531158 | Inhibition of Candida metapsilosis 960161 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID432859 | Ratio of free-drug Cmax in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 1.97 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID516194 | Antifungal activity against Candida parapsilosis 20489.085 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID522750 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 16 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID522761 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 32 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID544183 | Activity at Candida albicans 205 1,3-beta-D-glucan synthase subunit FKS1p T1933C mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID574345 | Fungicidal activity against Candida krusei isolate 1 assessed as log reduction in bacterial count at 4 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID574310 | Fungicidal activity against Candida krusei isolate ATCC 6258 assessed as log reduction in bacterial count at 4 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID555809 | Antimicrobial activity against Cunninghamella bertholletiae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID509662 | Antimicrobial activity against Candida tropicalis after 24 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID564444 | Drug level healthy human epithelial lining fluid at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions after 8 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID326115 | Paradoxical effect in Candida parapsilosis assessed as increase in turbidity at 16 times MIC | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. |
| AID433046 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 6.8 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432508 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 3.90 +/- 0.15 log10CFU per kidney administered intraperitoneally every 48 hrs up to 4 days mea | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544187 | Activity at Candida albicans 149 1,3-beta-D-glucan synthase subunit FKS1p G1942T mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID555620 | Antimicrobial activity against Fusarium verticillioides by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID324337 | Inhibition of glucan synthase in Candida albicans ATCC 90028 in presence of 20% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID433217 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 1.25 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans K-1 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433445 | Ratio of free-drug Cmax in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.95 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544338 | AUC (0 to t) in human plasma at 100 mg, iv by LC-MS/MS analysis | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID555626 | Antimicrobial activity against Phialemonium curvatum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID433663 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 11.8 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555585 | Antimicrobial activity against Dipodascus capitatus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID564250 | Tmax in healthy human at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID565362 | Antifungal activity against Candida dubliniensis 10033 after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID555591 | Antimicrobial activity against Rhodotorula mucilaginosa by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID555811 | Antimicrobial activity against Rhizomucor spp.by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID555796 | Antimicrobial activity against Scedosporium prolificans by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID374483 | Antifungal activity against Candida lusitaniae isolate 0013-002 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID433695 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans K-1 after 24 hr | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432656 | Ratio of Cmax in Candida glabrata 35315-infected neutropenic ICR/Swiss mouse candidiasis model at 6.4 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 35315 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID545283 | Antimicrobial activity against Candida albicans isolate S at 1 ug/ml grown on Muller-Hinton agar medium after 48 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID433428 | Ratio of free-drug Cmax in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 3.72 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID520620 | Antifungal activity against Candida metapsilosis by microdilution AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. |
| AID432848 | Ratio of free-drug Cmax in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID372838 | Ratio of MIC50 for Aspergillus flavus isolate 0001-033 in presence of 50% human serum to MIC50 for Aspergillus flavus isolate 0001-033 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID565396 | Antifungal activity against Candida dubliniensis FMR 10034 infected in immunosuppressed OF1 mouse assessed as fungal count in spleen at 1 mg/kg/day, iv after 24 hrs by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID571054 | Antifungal activity against Candida parapsilosis assessed as time period for bacterial regrowth inhibition after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432510 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as viral burden per kidney administered intraperitoneally once every 96 hrs measured per 96 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555607 | Antimicrobial activity against Aspergillus nidulans by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID433424 | Ratio of free-drug Cmax in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522804 | Inhibition of Candida glabrata CG-C3 wild type FKS | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID570882 | Antifungal activity against Candida albicans isolate 1 assessed as cell wall damage at 4 times MIC by Transmission electron microscopy | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID532041 | Antifungal activity against Lichtheimia ramosa clinical isolate after 24 hrs by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. |
| AID433432 | Ratio of free-drug Cmax in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 11.8 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432866 | Ratio of free-drug Cmax in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 6.8 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID565373 | Antifungal activity against Candida dubliniensis 10034 by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID113165 | In vivo antifungal activity administered orally against Candida albicans infections in mice. | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. |
| AID323363 | Antifungal activity against Candida glabrata 05-761 isolate assessed as decrease in fungal turbidity in presence of 50% mouse serum by microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID432501 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as viral burden per kidney administered intraperitoneally every 16 hrs up to 4 days measured per 96 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574326 | Fungicidal activity against Candida parapsilosis isolate A assessed as log reduction in bacterial count at 4 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID544174 | Activity at Candida albicans SC5314 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID433684 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 7.5 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5376 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531156 | Inhibition of Candida orthopsilosis 981224 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID545188 | Antimicrobial activity against Candida albicans isolate R infected in NMRI mouse assessed as decrease in kidney bacterial burden at 12 mg/kg, ip measured on day 4 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID433447 | Ratio of free-drug Cmax in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 2.31 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374503 | Antifungal activity against Candida tropicalis isolate 0022-021 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID432270 | Increase in metabolic activity of nongerminated Aspergillus terreus assessed as formation of short, stubby aberrant hyphae at 0.03 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID529452 | Antifungal activity against Aspergillus flavus | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Pharmacokinetics and tissue distribution of anidulafungin in rats. |
| AID432860 | Ratio of free-drug Cmax in Candida glabrata 5203-infected neutropenic ICR/Swiss mouse candidiasis model at 2.45 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5203 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433048 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.15 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-17 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID324326 | Inhibition of glucan synthase in Aspergillus fumigatus R21 in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID1717507 | Elimination half life life in iv dosed human | 2020 | Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21 | Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall. |
| AID433642 | Antifungal activity against Candida glabrata 35315 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID542418 | Antimicrobial activity against Aspergillus terreus environmental isolate after 48 hrs by EUCAST test | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing. |
| AID532044 | Antifungal activity against Lichtheimia corymbifera clinical isolate after 48 hrs by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID433649 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 3.72 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID582485 | Antifungal activity against Candida glabrata ATCC 90030 expressing wild type Fks1p and Fks2p by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID582487 | Antifungal activity against Candida glabrata isolate 3168 expressing wild type Fks1p and Fks2p by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID433025 | Ratio of AUC (0 to 24 hrs) in Candida tropicalis 98-234-infected neutropenic ICR/Swiss mouse candidiasis model at 3.81 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida tropicalis 98-234 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544337 | AUC (0 to infinity) in human plasma at 100 mg, iv by LC-MS/MS analysis | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID574349 | Antifungal activity against Candida parapsilosis isolate A assessed as time period for bacterial growth inhibition at 4 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID554490 | Antifungal activity against Aspergillus fumigatus Af293 expressing crzA gene assessed as abnormal hyphal growth by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. |
| AID555580 | Antimicrobial activity against Candida inconspicua by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID574121 | Fungicidal activity against Candida parapsilosis isolate A assessed as log reduction in bacterial count at MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433625 | Antifungal activity against Candida glabrata 33616 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID546071 | Antifungal activity against Clavispora lusitaniae isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID323331 | Antifungal activity against Candida dubliniensis SCS59662 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID555603 | Antimicrobial activity against Aspergillus fumigatus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID73758 | In vitro inhibition of glucan synthase obtained from Candida albicans at a concentration of 10 ug/mL. | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. |
| AID570858 | Increase in susceptibility to calcofluor white in Candida albicans ATCC 90028 assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID516187 | Antifungal activity against Candida parapsilosis 20477.078 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID518787 | Antifungal activity against Candida glabrata isolate 4690 expressing fks2 L644W mutant after 24 to 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. |
| AID433240 | Ratio of Cmax in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433864 | Ratio of antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model at 320 mg/kg/96 hrs, ip for 4 days to at 1.25 mg/kg/96 hrs, ip for 4 days | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID509655 | Antimicrobial activity against caspofungin-resistant Candida albicans CAI4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID323266 | Antifungal activity against Candida albicans SCS68858 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID574126 | Fungicidal activity against Candida parapsilosis isolate S assessed as log reduction in bacterial count at 4 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID529558 | Antimicrobial activity against Candida albicans grown as planktonic cell after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | In vitro activity of anidulafungin against Candida albicans biofilms. |
| AID544141 | Antimicrobial activity against Candida albicans 149 harboring FKS1 G1942T mutant gene and FKS1 hotspot1 D648Y mutant gene by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID575105 | Antifungal activity against Madurella mycetomatis isolate 35 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID531238 | Antifungal activity against Candida krusei after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID544171 | Inhibition of Candida albicans 90 1,3-beta-D-glucan synthase subunit FKS1p G4082R mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID351875 | Ratio of IC50 for Aspergillus fumigatus 1,3-beta-D-glucan synthase EMFR-S678P mutant to IC50 for Aspergillus fumigatus wild-type 1,3-beta-D-glucan synthase KU80delta | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. |
| AID545200 | Antimicrobial activity against Candida albicans isolate R at 5 ug/ml grown on RPMI 1640 medium after 48 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID571049 | Antifungal activity against Candida parapsilosis isolate A coincubated with mouse J774 macrophages assessed as macrophage induced bacterial cell killing at 4 times MIC (Rvb = 19 +/- 9 %) | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID565394 | Antifungal activity against Candida dubliniensis FMR 10032 infected in immunosuppressed OF1 mouse assessed as fungal count in spleen at 1 mg/kg/day, iv after 24 hrs by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID574319 | Fungicidal activity against Candida albicans ATCC 90028 assessed as log reduction in bacterial count at 4 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID543918 | Antimicrobial activity against Candida albicans 36082 by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID433066 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 2.45 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 513 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531233 | Antifungal activity against Candida tropicalis after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID559892 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as minimum concentration producing >= 50% growth reduction after 48 hrs by M27-A3 microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID432630 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as viral burden per kidney administered intraperitoneally once every 96 hrs measured per 96 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID549031 | Antimicrobial activity against Candida krusei LMR 39-14 infected in immunosuppressed CF-1 mouse assessed as serum 1,3-beta-D-glucan level at 20 mg/kg, ip administered once daily for 5 days measured after 10 days (Rvb= 5.22) | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. |
| AID323297 | Antifungal activity against Candida albicans Y109 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID574111 | Fungicidal activity against Candida albicans ATCC 90028 assessed as log reduction in bacterial count at 4 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID509650 | Antimicrobial activity against caspofungin-resistant Candida albicans T26 by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID564440 | Drug level healthy human plasma at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions after 8 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID432861 | Ratio of free-drug Cmax in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544178 | Activity at Candida albicans 3107 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID570849 | Increase in susceptibility to SDS in Candida krusei isolate ATCC 6258 assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522713 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as mild induction of fungal death at 0.03 to 32 mg/L after 6 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID432416 | Antifungal activity against germinated Aspergillus fumigatus assessed as absence of visual fungal growth at 64 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID582563 | Antifungal activity against Candida glabrata isolate 42997 expressing Fks1p F625S mutant and wild type Fks2p by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID433208 | Ratio of free-drug AUC (0 to 24 hrs) in Candida tropicalis 98-234-infected neutropenic ICR/Swiss mouse candidiasis model at 3.81 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida tropicalis 98-2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555573 | Antimicrobial activity against Candida kefyr by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID555588 | Antimicrobial activity against Galactomyces geotrichum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID582559 | Antifungal activity against Candida glabrata isolate 5416 expressing wild type Fks1p and Fks2p W1375L mutant by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID555866 | Antimicrobial activity against Beauveria bassiana by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID323341 | Antifungal activity against Candida krusei ATCC 6258 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID522754 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 4 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID432420 | Antifungal activity against germinated Aspergillus flavus assessed as absence of visual fungal growth at 64 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID582553 | Antifungal activity against Candida glabrata isolate 234 expressing wild type Fks1p and Fks2p F659V mutant by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID531155 | Inhibition of Candida orthopsilosis H10 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID531235 | Antifungal activity against Candida glabrata after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID574314 | Fungicidal activity against Candida krusei isolate 1 assessed as log reduction in bacterial count at MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID544415 | Selectivity ratio of Ki for Candida albicans 121 1,3-beta-D-glucan synthase subunit FKS1p G4082A mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID555593 | Antimicrobial activity against Trichosporon ovoides by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID433242 | Ratio of Cmax in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 13 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID565358 | Antifungal activity against Candida dubliniensis 10031 after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID432325 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as reduction of viral burden in kidney at 20 mg/kg, ip administered 2 hrs postinfection as single dose measured after 96 hrs post dosing by | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555810 | Antimicrobial activity against Rhizopus microsporus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID582556 | Antifungal activity against Candida glabrata isolate 41400 expressing wild type Fks1p and Fks2p D666G mutant by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID575120 | Antifungal activity against Madurella mycetomatis isolate 83 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID544156 | Inhibition of Candida albicans 90028 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID555798 | Antimicrobial activity against Alternaria infectoria by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID432418 | Antifungal activity against germinated Aspergillus terreus assessed as absence of visual fungal growth at 64 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID570866 | Increase in susceptibility to calcofluor white in Candida parapsilosis isolate A assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID509643 | Antimicrobial activity against caspofungin-resistant Candida albicans NR3 expressing homozygous fsk1 mutant gene by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID432844 | Ratio of free-drug Cmax in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 0.94 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555621 | Antimicrobial activity against Paecilomyces variotii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID521321 | Antimicrobial activity against Aspergillus flavus hyphae isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method in presence of voriconazole | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID544411 | Selectivity ratio of Ki for Candida albicans 89 1,3-beta-D-glucan synthase subunit FKS1p C1934A mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID433664 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 7.5 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID582557 | Antifungal activity against Candida glabrata isolate 42031 expressing wild type Fks1p and Fks2p D666E mutant by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID522799 | Inhibition of Candida albicans ATCC 90028 wild type FKS | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID433220 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 0.94 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans 580 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323268 | Antifungal activity against Candida albicans AM2003/0083 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID433414 | Ratio of free-drug Cmax in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID535612 | Antifungal activity against Candida albicans 42379 expressing FKS1 F645P mutant after 24 hrs by broth microdilution method in presence of 50% human serum | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID351873 | Inhibition of 1,3-beta-D-glucan synthase EMFR-S678P mutant from Aspergillus fumigatus assessed as incorporation of [3H]glucose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. |
| AID432648 | Ratio of Cmax in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 3.37 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID518070 | Protein binding in Candida albicans infected neutropenic ICR Swiss mouse at 80 mg/kg, ip | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID432626 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per 96 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID582582 | Inhibition of Candida glabrata isolate 3169 1,3-beta-D-glucan synthase Fks1p D632E mutant/wild type Fks2p | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID432485 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as suppression of fungal regrowth at 1.25 mg/kg, ip administered 2 hrs postinfection as single dose by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433218 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.15 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-17 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555583 | Antimicrobial activity against Candida pintolopesii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID522772 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 0.25 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID516200 | Cmax in Candida albicans infected neutropenic ICR Swiss mouse at 80 mg/kg, ip | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID570850 | Increase in susceptibility to SDS in Candida albicans isolate 1 assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432247 | Antifungal activity against germinated Aspergillus terreus assessed as lowest drug concentration that produced short, stubby and highly branched hyphae after 48 hrs by microscopic analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID374521 | Antifungal activity against Aspergillus fumigatus isolate 0002-020 after 24 hrs by CLSI M38-A broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID574130 | Fungicidal activity against Candida glabrata isolate 1 assessed as log reduction in bacterial count at MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID323265 | Antifungal activity against Candida albicans SCS68858 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID516197 | Antifungal activity against Candida orthopsilosis 20577.055 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID543926 | Antimicrobial activity against Candida albicans 3795 by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID432820 | Ratio of free-drug Cmax in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 1.97 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID521309 | Antimicrobial activity against Aspergillus flavus conidia isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID518786 | Antifungal activity against Candida glabrata isolate 4707 expressing fks2 S645P mutant after 24 to 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. |
| AID432645 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 1.83 +/- 0.54 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days me | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555625 | Antimicrobial activity against Trichoderma spp. by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID544318 | Inhibition of human CYP3A4 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID374492 | Antifungal activity against Candida parapsilosis isolate 0011-013 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID582587 | Inhibition of Candida glabrata isolate 3830 1,3-beta-D-glucan synthase wild type Fks1p/Fks2p S663P mutant | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID522728 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 1 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID323353 | Antifungal activity against Candida glabrata 05-62 isolate in presence of 5% mouse serum after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID432856 | Ratio of free-drug Cmax in Candida albicans 98-2200-infected neutropenic ICR/Swiss mouse candidiasis model at 3.37 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-2200 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544164 | Inhibition of Candida albicans 5415 1,3-beta-D-glucan synthase subunit FKS1p T1933C mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID433021 | Ratio of AUC (0 to 24 hrs) in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 1.25 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID575117 | Antifungal activity against Madurella mycetomatis isolate 64 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID545166 | Antimicrobial activity against Candida albicans isolate C after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID432474 | Drug level in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse serum at 1.25 mg/kg, ip administered 2 hrs postinfection as single dose | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID565391 | Antifungal activity against Candida dubliniensis FMR 10034 infected in OF1 mouse assessed as fungal count in kidney at 10 mg/kg/day, iv after 24 hrs by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID433241 | Ratio of Cmax in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.95 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555596 | Antimicrobial activity against Cryptococcus albidus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID574120 | Fungicidal activity against Candida parapsilosis isolate A assessed as log reduction in bacterial count at 4 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID565392 | Antifungal activity against Candida dubliniensis FMR 10034 infected in OF1 mouse assessed as fungal count in kidney at 1 mg/kg/day, iv after 24 hrs by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID509649 | Antimicrobial activity against caspofungin-resistant Candida albicans T25 by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID433212 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 1.58 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 32930 aft | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432298 | Antifungal activity against nongerminated Aspergillus fumigatus assessed as absence of visual fungal growth at 128 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID433225 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 1.58 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 32930 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID529546 | Antifungal activity against Candida glabrata 06-3170 harboring FSK1p T1896G and D632E mutant obtained from patient on compound therapy by M27-A2 method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID433427 | Ratio of free-drug Cmax in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 2.31 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531345 | Antimicrobial activity against Candida glabrata isolate 7755 FKS2 F659V mutant gene after 48 hrs by broth dilution method in presence of 50% of human serum | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. |
| AID544336 | Tmax in human plasma at 100 mg, iv by LC-MS/MS analysis | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID522741 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 32 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID432311 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432506 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per 96 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570862 | Increase in susceptibility to calcofluor white in Candida glabrata isolate 3 assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID559873 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 90% fungal growth reduction at 2 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID518793 | Antifungal activity against Candida albicans after 24 to 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. |
| AID565364 | Antifungal activity against Candida dubliniensis 10034 after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID433060 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 1.25 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans K-1 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID582576 | Inhibition of Candida glabrata ATCC 90030 wild type 1,3-beta-D-glucan synthase | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID535619 | Antifungal activity against Candida tropicalis T19 blood stream isolate harboring Fks1p FLTLS/PLRDP mutant protein | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID575110 | Antifungal activity against Madurella mycetomatis isolate 45 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID559033 | Plasma concentration in mouse infected with Candida albicans at 10 mg/kg, ip after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID433626 | Antifungal activity against Candida glabrata 34341 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID544133 | Antimicrobial activity against Candida albicans 205 harboring FKS1 T1933C mutant gene and FKS1 hotspot1 S645P mutant gene by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID323335 | Antifungal activity against Candida dubliniensis SCSBB417709 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID516199 | Antifungal activity against Candida parapsilosis 20435.057 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID555606 | Antimicrobial activity against Aspergillus niger by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID326109 | Antifungal activity against Candida glabrata after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. |
| AID323305 | Antifungal activity against Candida dubliniensis 910Aa after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID544162 | Inhibition of Candida albicans 2762 1,3-beta-D-glucan synthase subunit FKS1p T1922C mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID433407 | Ratio of Cmax in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 2.31 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323281 | Antifungal activity against Candida albicans T28 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID522881 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 1 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID559032 | Plasma concentration in mouse infected with Candida albicans at 10 mg/kg, ip after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID559657 | Antifungal activity against Candida krusei EU123 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID374480 | Ratio of MIC50 for Candida krusei isolate 0013-054 in presence of 50% human serum to MIC50 for Candida krusei isolate 0013-054 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID516177 | Antifungal activity against Candida glabrata 513 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID555630 | Antimicrobial activity against Hormographiella verticillata by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID432316 | Cmax in serum of neutropenic ICR/Swiss mouse candidiasis model at 20 mg/kg, ip up to 4 hrs by reverse-phase high-pressure liquid chromatography | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID554504 | Antifungal activity against cnaA deficient Aspergillus fumigatus Af293 assessed as inhibition of hyphal growth at germling stage at 1 ug/ml by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. |
| AID432251 | Ratio of log2 of MEC for germinated Aspergillus flavus to log2 of MEC for nongerminated Aspergillus flavus | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID433422 | Ratio of free-drug Cmax in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 11.8 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433691 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 4.21 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 33609 aft | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531236 | Antifungal activity against Candida parapsilosis after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID323357 | Antifungal activity against Candida glabrata 05-62 isolate in presence of 50% human serum after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID574102 | Antifungal activity against Candida glabrata isolate 1 by CLSI M27-A3 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID543925 | Antimicrobial activity against Candida albicans 3107 by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID324338 | Inhibition of glucan synthase in Candida albicans ATCC 90028 in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID582558 | Antifungal activity against Candida glabrata isolate 51916 expressing wild type Fks1p and Fks2p P667T mutant by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID433862 | Antifungal activity against Candida glabrata after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID543924 | Antimicrobial activity against Candida albicans 3107 by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID555800 | Antimicrobial activity against Aureobasidium pullulans by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID509672 | Antimicrobial activity against Clavispora lusitaniae ATCC 42720 after 24 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID522746 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 32 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID531161 | Inhibition of FKS1 deficient Saccharomyces cerevisiae BY4742 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID559666 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 90% fungal growth reduction at 0.12 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID555586 | Antimicrobial activity against Saccharomyces cerevisiae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID323306 | Antifungal activity against Candida dubliniensis 910Aa after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID522731 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 32 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID432639 | Antifungal activity against Candida glabrata 513 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 1.83 +/- 0.54 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days mea | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555618 | Antimicrobial activity against Fusarium proliferatum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID516192 | Antifungal activity against Candida parapsilosis 20562.03 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID535406 | Antifungal activity against Candida albicans 2762 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID432314 | AUC (0 to infinity) in serum of neutropenic ICR/Swiss mouse candidiasis model at 80 mg/kg, ip by reverse-phase high-pressure liquid chromatography | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544175 | Activity at Candida albicans 36082 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID433238 | Antifungal activity against Candida glabrata 5592 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432259 | Effect on nongerminated Aspergillus flavus metabolic activity assessed as drug concentration at which fungal metabolic activity occurs after 2 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID544158 | Inhibition of Candida albicans 3107 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID432473 | Drug level in Candida albicans K-1 infected neutropenic ICR/Swiss mouse serum at 20 mg/kg, ip administered 2 hrs postinfection as single dose measured after 12 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID516173 | Antifungal activity against Candida albicans 98-234 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID433439 | Ratio of free-drug Cmax in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 4.13 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID564447 | Drug level healthy human alveolar macrophage at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions after 4 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID374482 | Ratio of MIC50 for Candida krusei ATCC 6258 in presence of 50% human serum to MIC50 for Candida krusei ATCC 6258 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID324349 | Ratio of MIC for Aspergillus flavus to MIC for Aspergillus niger in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID425793 | Antifungal activity against Candida albicans GDH2346 grown as biofilm assessed as maximum inhibition of biofilm metabolic activity at 8 mg/liter after 24 hrs by XTT assay relative to control | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID521318 | Antimicrobial activity against Aspergillus niger hyphae isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID374518 | Antifungal activity against Aspergillus fumigatus isolate 0020-018 after 24 hrs by CLSI M38-A broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID425782 | Antifungal activity against Candida parapsilosis PA/71 grown as planktonic cell assessed as minimum drug level required to decrease turbidity by 50% after 24 hrs by CLSI M27-A2 method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID555799 | Antimicrobial activity against Exophiala dermatitidis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID432480 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as reduction of viral burden in kidney at 20 mg/kg, ip administered 2 hrs postinfection as single dose measured within 1 to 4 hrs post dos | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID582569 | Antifungal activity against Candida glabrata isolate 234 expressing wild type Fks1p and Fks2p F659V mutant by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID432262 | Induction of maximal metabolic inhibition in nongerminated Aspergillus fumigatus assessed as minimal metabolic activity Ymin after 2 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID433419 | Ratio of free-drug Cmax in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 4.13 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574101 | Antifungal activity against Candida parapsilosis isolate S by CLSI M27-A3 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432271 | Increase in metabolic activity of germinated Aspergillus terreus assessed as formation of short, stubby aberrant hyphae at 0.03 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID564441 | Drug level healthy human plasma at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions after 12 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID433042 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 1.58 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555568 | Antimicrobial activity against Candida tropicalis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID433408 | Ratio of Cmax in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 3.72 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433057 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 35315-infected neutropenic ICR/Swiss mouse candidiasis model at 6.4 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 35315 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID575113 | Antifungal activity against Madurella mycetomatis isolate 50 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID374497 | Antifungal activity against Candida parapsilosis isolate 0036-030 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID545152 | Antimicrobial activity against Candida albicans isolate R after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID509663 | Antimicrobial activity against Candida glabrata after 24 hrs by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID535617 | Antifungal activity against Candida tropicalis T7 blood stream isolate | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID323328 | Antifungal activity against Candida dubliniensis SCS17154969-1 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID535613 | Antifungal activity against Candida albicans 53264 expressing FKS1 F645P mutant after 24 hrs by broth microdilution method in presence of 50% human serum | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID559867 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 99.9% fungal growth reduction at 0.5 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID323283 | Antifungal activity against Candida albicans T32 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID324323 | Inhibition of glucan synthase in Aspergillus fumigatus R21 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID521320 | Antimicrobial activity against Aspergillus terreus hyphae isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method in presence of voriconazole | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID324324 | Inhibition of glucan synthase in Aspergillus fumigatus R21 in presence of 10% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID570886 | Inhibition of Candida albicans isolate 1 adherence to human buccal epithelial cells at 4 times MIC after 1 hr by adherence assay relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID531159 | Inhibition of Saccharomyces cerevisiae BY4742 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID323286 | Antifungal activity against Candida albicans NR2 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID432322 | Protein binding in mouse serum by equilibrium dialysis | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433668 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 2.31 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans 580 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574338 | Fungicidal activity against Candida glabrata isolate 2 assessed as log reduction in bacterial count at 4 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID374485 | Ratio of MIC50 for Candida lusitaniae isolate 0013-002 in presence of 50% human serum to MIC50 for Candida lusitaniae isolate 0013-002 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID574131 | Fungicidal activity against Candida glabrata isolate 2 assessed as log reduction in bacterial count at 16 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID554494 | Antifungal activity against Aspergillus fumigatus H237 expressing dominant-active rasA gene assessed as abnormal hyphal growth by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. |
| AID432472 | Drug level in Candida albicans K-1 infected neutropenic ICR/Swiss mouse serum at 5 mg/kg, ip administered 2 hrs postinfection as single dose | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID559026 | Plasma concentration in mouse infected with Candida albicans at 5 mg/kg, ip after 6 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID433229 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 6.8 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5376 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374479 | Antifungal activity against Candida krusei isolate 0013-054 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID516175 | Antifungal activity against Candida albicans 570 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID549026 | Antimicrobial activity against Candida krusei LMR 39-14 infected in immunosuppressed CF-1 mouse assessed as serum 1,3-beta-D-glucan level at 10 mg/kg, ip administered once daily for 5 days measured after 5 days (Rvb= 6.66) | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. |
| AID433636 | Antifungal activity against Candida glabrata 570 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522771 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 32 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID555575 | Antimicrobial activity against Candida famata by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID509660 | Antimicrobial activity against Candida parapsilosis after 24 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID543923 | Antimicrobial activity against Candida albicans 1002 by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID432826 | Ratio of free-drug Cmax in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 3.57 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID45483 | Antifungal activity against Candida albicans | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. |
| AID432324 | Protein binding in Candida albicans K-1 infected neutropenic ICR/Swiss mouse serum after 30 mins by arithmetic dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432857 | Ratio of free-drug Cmax in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 0.94 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433658 | Ratio of AUC (0 to 24 hrs) in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 2.31 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323271 | Antifungal activity against Candida albicans HK04M102095 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID582590 | Inhibition of Candida glabrata isolate 51916 1,3-beta-D-glucan synthase wild type Fks1p/Fks2p P667T mutant | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID518090 | Antifungal activity against Candida glabrata infected in ICR Swiss mouse | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID374478 | Antifungal activity against Candida krusei isolate 0013-054 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID323326 | Antifungal activity against Candida dubliniensis Leic952 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID432265 | Induction of maximal metabolic inhibition in germinated Aspergillus terreus assessed as minimal metabolic activity Ymin after 2 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID544186 | Activity at Candida albicans 85 1,3-beta-D-glucan synthase subunit FKS1p C1934T mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID432629 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 48 hrs up to 4 days measured per 96 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433043 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 34341-infected neutropenic ICR/Swiss mouse candidiasis model at 6.9 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 34341 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID545207 | Antimicrobial activity against Candida albicans isolate S at 25 ug/ml grown on RPMI 1640 medium after 24 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID432414 | Antifungal activity against germinated Aspergillus flavus assessed as absence of visual fungal growth at 128 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID509654 | Antimicrobial activity against caspofungin-resistant Candida albicans T32 by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID433855 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 3.31 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 32930 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433069 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 34341-infected neutropenic ICR/Swiss mouse candidiasis model at 6.9 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 34341 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574346 | Fungicidal activity against Candida krusei isolate 1 assessed as log reduction in bacterial count at MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID555804 | Antimicrobial activity against Scytalidium hyalinum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID516185 | Antifungal activity against Candida metapsilosis 20463.02 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID432490 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as prolongation of fungal growth suppression at 5 mg/kg, ip administered 2 hrs postinfection as single dose by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432833 | Ratio of free-drug Cmax in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 1.97 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574119 | Fungicidal activity against Candida parapsilosis isolate A assessed as log reduction in bacterial count at 16 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID425780 | Antifungal activity against Candida albicans M61 grown as planktonic cell assessed as minimum drug level required to decrease turbidity by 50% after 24 hrs by CLSI M27-A2 method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID323293 | Antifungal activity against Candida albicans T25 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID582488 | Antifungal activity against Candida glabrata isolate 42997 expressing Fks1p F625S mutant and wild type Fks2p by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID570873 | Increase in susceptibility to calcofluor white in Candida parapsilosis isolate A assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID582577 | Inhibition of Candida glabrata isolate 218 wild type 1,3-beta-D-glucan synthase | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID570885 | Antifungal activity against Candida krusei isolate 1 assessed as cell wall damage at 4 times MIC by Transmission electron microscopy | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522691 | Fungicidal activity against Candida orthopsilosis isolate CP-151 bloodstream form by CLSI method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID545016 | Volume of distribution at steady state in human plasma at 100 mg, iv by LC-MS/MS analysis | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID432246 | Antifungal activity against nongerminated Aspergillus terreus assessed as lowest drug concentration that produced short, stubby and highly branched hyphae after 48 hrs by microscopic analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID351871 | Antifungal activity against Aspergillus fumigatus expressing fks1 gene EMFR-S678P/WT mutant after 24 to 48 hrs by broth dilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. |
| AID570871 | Increase in susceptibility to calcofluor white in Candida albicans isolate 1 assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID582561 | Antifungal activity against Candida glabrata isolate 218 expressing wild type Fks1p and Fks2p by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID323313 | Antifungal activity against Candida dubliniensis FS after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID374505 | Ratio of MIC50 for Candida tropicalis isolate 0022-021 in presence of 50% human serum to MIC50 for Candida tropicalis isolate 0022-021 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID433640 | Antifungal activity against Candida glabrata 33616 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570830 | Antifungal activity against Candida albicans ATCC 90028 assessed as time period for bacterial growth inhibition at 16 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432321 | Elimination half life in serum of neutropenic ICR/Swiss mouse candidiasis model at 5 mg/kg, ip by reverse-phase high-pressure liquid chromatography | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374487 | Antifungal activity against Candida lusitaniae isolate 0015-049 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID324340 | Inhibition of glucan synthase in Candida albicans ATCC 36082 in presence of 10% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID545208 | Antimicrobial activity against Candida albicans isolate S at 1 ug/ml grown on Muller-Hinton agar medium after 24 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID432665 | Ratio of Cmax in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 2.45 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID575107 | Antifungal activity against Madurella mycetomatis isolate 39 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID432853 | Ratio of free-drug Cmax in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 6.8 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID521319 | Antimicrobial activity against Aspergillus fumigatus hyphae isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method in presence of voriconazole | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID432299 | Antifungal activity against Candida albicans 98-17 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544138 | Antimicrobial activity against Candida albicans 85 harboring FKS1 C1934T mutant gene and FKS1 hotspot1 S645F mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID535621 | Antifungal activity against Candida albicans ATCC 90028 | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID522795 | Inhibition of Candida tropicalis CT-C1 FKS1 T227C mutant | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID574118 | Fungicidal activity against Candida albicans isolate 2 assessed as log reduction in bacterial count at MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID582555 | Antifungal activity against Candida glabrata isolate 3830 expressing wild type Fks1p and Fks2p S663P mutant by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID522801 | Inhibition of Candida albicans 205 FKS1 T1933C mutant | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID522745 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 16 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID374342 | Antifungal activity against Candida glabrata isolate 0022-012 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID374484 | Antifungal activity against Candida lusitaniae isolate 0013-002 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID432493 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as prolongation of fungal growth suppression at 5 mg/kg, ip administered 2 hrs postinfection as single dose by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432846 | Ratio of free-drug Cmax in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 1.97 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID582583 | Inhibition of Candida glabrata isolate 42971 1,3-beta-D-glucan synthase Fks1p D632Y mutant/Fks2p R1377STOP mutant | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID432303 | Antifungal activity against Candida glabrata 570 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID535625 | Inhibition of Candida tropicalis T3 blood stream isolate glucan synthase subunit FKS1p with FLTLS/PLRDP mutant at monophasic kinetics | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID433440 | Ratio of free-drug Cmax in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 4.21 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323318 | Antifungal activity against Candida dubliniensis J930936 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID323349 | Antifungal activity against Candida glabrata 05-761 isolate in presence of 5% mouse serum after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID545284 | Antimicrobial activity against Candida albicans isolate S at 5 ug/ml grown on Muller-Hinton agar medium after 48 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID570831 | Antifungal activity against Candida parapsilosis isolate A assessed as time period for bacterial growth inhibition at 16 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433686 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.95 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-17 aft | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570856 | Increase in susceptibility to SDS in Candida krusei isolate ATCC 6258 assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID544315 | Inhibition of human CYP2C9 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID575122 | Inhibition of beta-1,3-D-glucan synthesis in Madurella mycetomatis isolate 55 after 7 days by alanine blue assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID433219 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 3.37 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-210 af | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID521308 | Antimicrobial activity against Aspergillus terreus conidia isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID565389 | Antifungal activity against Candida dubliniensis FMR 10032 infected in OF1 mouse assessed as fungal count in spleen at 10 mg/kg/day, iv after 24 hrs by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID565371 | Antifungal activity against Candida dubliniensis 10032 by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID509639 | Antimicrobial activity against caspofungin-resistant Candida albicans CAI4R1 expressing heterozygous fsk1 mutant gene by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID433226 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 34341-infected neutropenic ICR/Swiss mouse candidiasis model at 6.9 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 34341 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574107 | Fungicidal activity against Candida albicans isolate S assessed as log reduction in bacterial count at 16 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433452 | Ratio of free-drug Cmax in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 11.8 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433859 | Steady state AUC in human at 100 mg/day | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432660 | Ratio of Cmax in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.15 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433059 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 6.8 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5376 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531166 | Inhibition of Candida glabrata ATCC 90030 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID522760 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 16 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID433030 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 34341-infected neutropenic ICR/Swiss mouse candidiasis model at 6.9 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 34341 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432515 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 16 hrs up to 4 days measured per 96 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374501 | Antifungal activity against Candida parapsilosis ATCC 22019 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID432829 | Ratio of free-drug Cmax in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.15 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID543916 | Antimicrobial activity against Candida albicans SC5314 by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID565363 | Antifungal activity against Candida dubliniensis 10033 after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID432323 | Protein binding in human serum by equilibrium dialysis | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323262 | Antifungal activity against Candida albicans SCS140136P after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID323307 | Antifungal activity against Candida dubliniensis AMCC after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID522751 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 32 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID432643 | Antifungal activity against Candida glabrata 35315 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 1.83 +/- 0.54 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days m | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID559866 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 99% fungal growth reduction at 0.5 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID432315 | Elimination half life in serum of neutropenic ICR/Swiss mouse candidiasis model at 80 mg/kg, ip by reverse-phase high-pressure liquid chromatography | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574344 | Fungicidal activity against Candida krusei isolate 1 assessed as log reduction in bacterial count at 16 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID564251 | AUC (0 to t) in healthy human at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID516195 | Antifungal activity against Candida parapsilosis 20511.092 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID522747 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 0.25 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID433644 | Antifungal activity against Candida glabrata 5376 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531137 | Antifungal activity against Candida parapsilosis H4 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID323273 | Antifungal activity against Candida albicans JIMS101103 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID1717629 | Antifungal activity against Candida albicans CY1002 infected in iv dosed ICR mouse administered as single dose measured on day 7 | 2020 | Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21 | Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall. |
| AID570874 | Increase in susceptibility to calcofluor white in Candida parapsilosis isolate 1 assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433683 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 11.8 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5592 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID534351 | Antifungal activity against Candida albicans TDH3 overexpressing FKS1 gene | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. |
| AID574320 | Fungicidal activity against Candida albicans isolate 1 assessed as log reduction in bacterial count at 16 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432664 | Ratio of Cmax in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 1.97 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID565359 | Antifungal activity against Candida dubliniensis 10031 after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID432511 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 3.90 +/- 0.15 log10CFU per kidney administered intraperitoneally once every 96 hrs measured pe | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433437 | Ratio of free-drug Cmax in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 2.31 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544140 | Antimicrobial activity against Candida albicans 149 harboring FKS1 G1942T mutant gene and FKS1 hotspot1 D648Y mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID522800 | Inhibition of Candida albicans 177 FKS1 T1922C mutant | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID323301 | Antifungal activity against Candida dubliniensis 81/060 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID529668 | Antimicrobial activity against Paecilomyces lilacinus by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Susceptibility testing and molecular classification of Paecilomyces spp. |
| AID574321 | Fungicidal activity against Candida albicans isolate 1 assessed as log reduction in bacterial count at 4 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID323285 | Antifungal activity against Candida albicans NR2 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID522724 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 4 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID432412 | Antifungal activity against germinated Aspergillus terreus assessed as absence of visual fungal growth at 128 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID433405 | Ratio of Cmax in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.95 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432411 | Antifungal activity against nongerminated Aspergillus terreus assessed as absence of visual fungal growth at 128 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID432277 | Increase in metabolic activity of germinated Aspergillus terreus assessed as elongation of short, stubby aberrant hyphae at 2 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID565395 | Antifungal activity against Candida dubliniensis FMR 10034 infected in immunosuppressed OF1 mouse assessed as fungal count in kidney at 1 mg/kg/day, iv after 24 hrs by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID432649 | Ratio of Cmax in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 0.94 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433441 | Ratio of free-drug Cmax in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 3.31 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID535412 | Antifungal activity against Candida albicans 42996 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID564442 | Drug level healthy human plasma at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions after 24 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID559029 | Plasma concentration in mouse infected with Candida albicans at 10 mg/kg, ip after 1 hr | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID582554 | Antifungal activity against Candida glabrata isolate 41026 expressing wild type Fks1p and Fks2p F659S mutant by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID574309 | Fungicidal activity against Candida krusei isolate ATCC 6258 assessed as log reduction in bacterial count at 16 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522770 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 16 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID540209 | Volume of distribution at steady state in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID432845 | Ratio of free-drug Cmax in Candida tropicalis 98-234-infected neutropenic ICR/Swiss mouse candidiasis model at 3.81 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida tropicalis 98-234 after 24 h | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID372841 | Ratio of MIC50 for Aspergillus flavus isolate 0001-061 in presence of 50% human serum to MIC50 for Aspergillus flavus isolate 0001-061 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID555628 | Antimicrobial activity against Fusarium equiseti by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID326124 | Paradoxical effect in Candida glabrata assessed as increase in turbidity at 16 times MIC | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. |
| AID570835 | Antifungal activity against Candida krusei isolate ATCC 6258 assessed as time period for bacterial growth inhibition at 16 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID323356 | Antifungal activity against Candida glabrata 05-761 isolate in presence of 50% human serum after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID433653 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 11.8 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID565361 | Antifungal activity against Candida dubliniensis 10032 after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID522692 | Fungicidal activity against Candida orthopsilosis isolate ATC194 bloodstream form by CLSI method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID432503 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 16 hrs up to 4 days measured per 96 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432657 | Ratio of Cmax in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 3.57 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID516198 | Antifungal activity against Candida parapsilosis 20519.069 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID544130 | Antimicrobial activity against Candida albicans 2762 harboring FKS1 T1922C mutant gene and FKS1 hotspot1 F641S mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID582589 | Inhibition of Candida glabrata isolate 42031 1,3-beta-D-glucan synthase wild type Fks1p/Fks2p D666E mutant | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID432479 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as reduction of viral burden in kidney at 1.25 mg/kg, ip administered 2 hrs postinfection as single dose measured within 1 to 4 hrs post do | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433239 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433045 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 3.57 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432307 | Antifungal activity against Candida glabrata 33616 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID529559 | Antimicrobial activity against Candida albicans grown as sessile cell after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | In vitro activity of anidulafungin against Candida albicans biofilms. |
| AID535422 | Antifungal activity against Candida albicans 41301 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method in presence of 50% human serum | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID582584 | Inhibition of Candida glabrata isolate 31498 1,3-beta-D-glucan synthase wild type Fks1p/Fks2p F659 deletion mutant | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID535418 | Antifungal activity against Candida albicans 4715 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method in presence of 50% human serum | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID433438 | Ratio of free-drug Cmax in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 3.72 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522763 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 1 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID323274 | Antifungal activity against Candida albicans JIMS101103 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID432849 | Ratio of free-drug Cmax in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 1.58 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432254 | Effect on germinated Aspergillus fumigatus metabolic activity assessed as drug concentration at which fungal metabolic activity occurs after 2 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID545330 | Antimicrobial activity against Candida albicans isolate C after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID559027 | Plasma concentration in mouse infected with Candida albicans at 5 mg/kg, ip after 12 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID574336 | Fungicidal activity against Candida glabrata isolate 1 assessed as log reduction in bacterial count at MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID574350 | Antifungal activity against Candida parapsilosis isolate 1 assessed as time period for bacterial growth inhibition at 4 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID554488 | Antifungal activity against Aspergillus fumigatus Af293 expressing cnaA gene assessed as abnormal hyphal growth by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. |
| AID555605 | Antimicrobial activity against Aspergillus flavus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID522725 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 16 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID544145 | Antimicrobial activity against Candida albicans 121 harboring FKS1 G4082A mutant gene and FKS1 hotspot2 R1361H mutant gene by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID516193 | Antifungal activity against Candida parapsilosis 20553.009 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID531144 | Antifungal activity against Saccharomyces cerevisiae BY4742-FKS1P649A mutant by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID544148 | Antimicrobial activity against Candida albicans 90 harboring FKS1 G4082R mutant gene and FKS1 hotspot2 R1361R/H mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID323319 | Antifungal activity against Candida dubliniensis J931021 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID374509 | Antifungal activity against Aspergillus terreus isolate 0031-087 after 48 hrs by CLSI M38-A broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID432285 | Increase in metabolic activity of germinated Aspergillus flavus assessed as elongation of short, stubby aberrant hyphae at 16 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID432282 | Increase in metabolic activity of nongerminated Aspergillus terreus assessed as elongation of short, stubby aberrant hyphae at 16 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID374490 | Ratio of MIC50 for Candida parapsilosis isolate 0014-074 in presence of 50% human serum to MIC50 for Candida parapsilosis isolate 0014-074 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID433231 | Antifungal activity against Candida albicans 98-17 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570851 | Increase in susceptibility to SDS in Candida albicans ATCC 90028 assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID531341 | Antimicrobial activity against Candida glabrata isolate 7755 expressing FKS2 F659V mutant gene after 24 hrs by broth dilution method in presence of 50% of human serum | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. |
| AID570857 | Increase in susceptibility to calcofluor white in Candida albicans isolate 1 assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID582560 | Antifungal activity against Candida glabrata ATCC 90030 expressing wild type Fks1p and Fks2p by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID565384 | Antifungal activity against Candida dubliniensis 10033 assessed as compound concentration at which paradoxical growth of observed after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID545329 | Antimicrobial activity against Candida albicans isolate R after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID433657 | Ratio of AUC (0 to 24 hrs) in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 13 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID516202 | Cmax in Candida albicans infected neutropenic ICR Swiss mouse at 5 mg/kg, ip | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID546082 | Antifungal activity against Candida krusei ATCC 6258 isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID433035 | Ratio of AUC (0 to 24 hrs) in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.15 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433410 | Ratio of Cmax in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 4.21 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID559658 | Fungicidal activity against Candida krusei EU123 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID555616 | Antimicrobial activity against Penicillium spp. by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID432842 | Ratio of free-drug Cmax in Candida albicans 98-207-infected neutropenic ICR/Swiss mouse candidiasis model at 1.15 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-207 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID582562 | Antifungal activity against Candida glabrata isolate 3168 expressing wild type Fks1p and Fks2p by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID433037 | Ratio of AUC (0 to 24 hrs) in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 0.94 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522739 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 4 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID518089 | Antifungal activity against Candida albicans infected in ICR Swiss mouse | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID433051 | Ratio of free-drug AUC (0 to 24 hrs) in Candida tropicalis 98-234-infected neutropenic ICR/Swiss mouse candidiasis model at 3.81 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida tropicalis 98-23 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID535414 | Antifungal activity against Candida albicans 53264 expressing FKS1 F645P mutant after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID351869 | Antifungal activity against Aspergillus fumigatus expressing wild-type fks1 gene KU80delta after 24 to 48 hrs by broth dilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. |
| AID545199 | Antimicrobial activity against Candida albicans isolate R at 1 ug/ml grown on RPMI 1640 medium after 48 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID432646 | Ratio of Cmax in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 1.25 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID559651 | Antifungal activity against Candida krusei CK2 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID433858 | Cmax in human at 100 mg/day | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433651 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 4.21 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID564446 | Drug level healthy human epithelial lining fluid at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions after 24 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID522696 | Fungicidal activity against Candida parapsilosis isolate CP-300 bloodstream form by CLSI method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID432828 | Ratio of free-drug Cmax in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 1.25 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433854 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 4.21 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 33609 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570883 | Antifungal activity against Candida parapsilosis isolate A assessed as cell wall damage at 4 times MIC by Transmission electron microscopy | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432654 | Ratio of Cmax in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 1.58 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374336 | Antifungal activity against Candida albicans isolate 0012-025 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID535624 | Inhibition of Candida tropicalis T7 blood stream isolate glucan synthase subunit FKS1p at monophasic kinetics | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID374515 | Antifungal activity against Aspergillus fumigatus isolate 0002-0016 after 24 hrs by CLSI M38-A broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID571048 | Antifungal activity against Candida albicans isolate 1 coincubated with mouse J774 macrophages assessed as macrophage induced bacterial cell killing at 4 times MIC (Rvb = 14 +/- 8 %) | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID559656 | Fungicidal activity against Candida krusei CK18 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID374346 | Ratio of MIC50 for Candida glabrata isolate 0049-038 in presence of 50% human serum to MIC50 for Candida glabrata isolate 0049-038 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID529566 | Total body clearance in F344 rat at 5 mg/kg, iv administered as single bolus dose | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Pharmacokinetics and tissue distribution of anidulafungin in rats. |
| AID433689 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 3.72 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 570 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433635 | Antifungal activity against Candida tropicalis 98-234 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544144 | Antimicrobial activity against Candida albicans 121 harboring FKS1 G4082A mutant gene and FKS1 hotspot2 R1361H mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID582575 | Antifungal activity against Candida glabrata isolate 5416 expressing wild type Fks1p and Fks2p W1375L mutant by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID432413 | Antifungal activity against nongerminated Aspergillus flavus assessed as absence of visual fungal growth at 128 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID518782 | Antifungal activity against Candida albicans isolate 4700 expressing fks1 F641Y mutant after 24 to 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. |
| AID555578 | Antimicrobial activity against Candida norvegensis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID555576 | Antimicrobial activity against Candida pelliculosa by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID324348 | Ratio of MIC for Aspergillus flavus to MIC for Aspergillus flavus in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID433453 | Ratio of free-drug Cmax in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 7.5 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522756 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 32 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID574334 | Fungicidal activity against Candida glabrata isolate 1 assessed as log reduction in bacterial count at 16 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433688 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 2.31 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans 580 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID555802 | Antimicrobial activity against Cladosporium spp. by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID544159 | Inhibition of Candida albicans 3795 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID574109 | Fungicidal activity against Candida albicans isolate S assessed as log reduction in bacterial count at MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID544409 | Selectivity ratio of Ki for Candida albicans 205 1,3-beta-D-glucan synthase subunit FKS1p T1933C mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID433034 | Ratio of AUC (0 to 24 hrs) in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 1.25 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323299 | Antifungal activity against Candida dubliniensis 75/043 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID531163 | Inhibition of Candida albicans ATCC 90028 glucan synthase assessed as [3H]UDPG incorporation | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID433671 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 4.21 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 33609 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433443 | Ratio of free-drug Cmax in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 7.5 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432513 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as viral burden per kidney administered intraperitoneally every 16 hrs up to 4 days measured per 96 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522752 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 0.25 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID433639 | Antifungal activity against Candida glabrata 32930 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522695 | Fungicidal activity against Candida metapsilosis isolate ATC193 bloodstream form by CLSI method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID559039 | Antifungal activity against Candida albicans | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID555812 | Antimicrobial activity against Saksenaea vasiformis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID545198 | Antimicrobial activity against Candida albicans isolate R at 25 ug/ml grown on Muller-Hinton agar medium after 24 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID545206 | Antimicrobial activity against Candida albicans isolate S at 5 ug/ml grown on RPMI 1640 medium after 24 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID564252 | Volume of distribution at steady state in healthy human at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID323287 | Antifungal activity against Candida albicans NR3 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID535411 | Antifungal activity against Candida albicans 43001 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID564249 | Cmax in healthy human at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID432669 | Ratio of Cmax in Candida glabrata 35315-infected neutropenic ICR/Swiss mouse candidiasis model at 6.4 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 35315 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID516179 | Antifungal activity against Candida glabrata 32930 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID518790 | Antifungal activity against Candida krusei after 24 to 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. |
| AID544136 | Antimicrobial activity against Candida albicans 89 harboring FKS1 C1934A mutant gene and FKS1 hotspot1 S645Y mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID574099 | Antifungal activity against Candida parapsilosis isolate A by CLSI M27-A3 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522689 | Fungicidal activity against Candida orthopsilosis isolate CP-131 bloodstream form by CLSI method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID509645 | Antimicrobial activity against caspofungin-resistant Candida albicans T32 by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID559028 | Plasma concentration in mouse infected with Candida albicans at 5 mg/kg, ip after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID432486 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as suppression of fungal regrowth at 20 mg/kg, ip administered 2 hrs postinfection as single dose by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID324319 | Inhibition of glucan synthase in Candida albicans 36082 assessed as incorporation of [3H]uridine diphosphoglucose in presence of 10% serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID374496 | Ratio of MIC50 for Candida parapsilosis isolate 0026-003 in presence of 50% human serum to MIC50 for Candida parapsilosis isolate 0026-003 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID432300 | Antifungal activity against Candida albicans 98-210 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374493 | Ratio of MIC50 for Candida parapsilosis isolate 0011-013 in presence of 50% human serum to MIC50 for Candida parapsilosis isolate 0011-013 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID544127 | Antimicrobial activity against Candida albicans 119 harboring FKS1 T1921C mutant gene and FKS1 hotspot1 F641L mutant gene by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID521317 | Antimicrobial activity against Aspergillus flavus hyphae isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID432628 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 3.90 +/- 0.15 log10CFU per kidney administered intraperitoneally every 48 hrs up to 4 days me | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433616 | Antifungal activity against Candida albicans K-1 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID531338 | Antimicrobial activity against Candida glabrata isolate 7754 after 24 hrs by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. |
| AID325031 | Antifungal activity against FKS1 T2080K mutation containing Candida krusei 100 isolate from acute myelogenous leukemia patient by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. |
| AID545168 | Antimicrobial activity against Candida albicans isolate C at 0.5 ug/ml after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID545203 | Antimicrobial activity against Candida albicans isolate R at 5 ug/ml grown on Muller-Hinton agar medium after 48 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID564450 | Drug level healthy human alveolar macrophage at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions after 24 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID574335 | Fungicidal activity against Candida glabrata isolate 1 assessed as log reduction in bacterial count at 4 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522708 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as inhibition of fungal regrowth at 0.03 to 32 mg/L after 6 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID432854 | Ratio of free-drug Cmax in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 1.25 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans K-20 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432632 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally once every 96 hrs measured per 96 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID351874 | Inhibition of 1,3-beta-D-glucan synthase EMFR-S678P/WT mutant from Aspergillus fumigatus assessed as incorporation of [3H]glucose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. |
| AID535626 | Inhibition of Candida tropicalis T3 blood stream isolate glucan synthase subunit FKS1p with FLTLS/PLRDP mutant at biphasic kinetics | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID15693 | Calculated partition coefficient (clogP) | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. |
| AID574318 | Fungicidal activity against Candida albicans ATCC 90028 assessed as log reduction in bacterial count at 16 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522734 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 4 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID565356 | Antifungal activity against Candida dubliniensis 9456 after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID433056 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 34341-infected neutropenic ICR/Swiss mouse candidiasis model at 6.9 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 34341 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574327 | Fungicidal activity against Candida parapsilosis isolate A assessed as log reduction in bacterial count at MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID559018 | Antifungal activity against Candida albicans infected in mouse assessed as fungal load in brain at 10 mg/kg, ip after 10 days | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID323309 | Antifungal activity against Candida dubliniensis ANSA 23a after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID559652 | Fungicidal activity against Candida krusei CK2 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID374507 | Antifungal activity against Candida tropicalis isolate 0050-028 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID374341 | Antifungal activity against Candida glabrata isolate 0022-012 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID535413 | Antifungal activity against Candida albicans 42379 expressing FKS1 F645P mutant after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID543927 | Antimicrobial activity against Candida albicans 3795 by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID582573 | Antifungal activity against Candida glabrata isolate 42031 expressing wild type Fks1p and Fks2p D666E mutant by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID324325 | Inhibition of glucan synthase in Aspergillus fumigatus R21 in presence of 20% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID522707 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as induction of miniparadoxical effect at 32 mg/L after 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID433669 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 3.72 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 570 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID535420 | Antifungal activity against Candida albicans 32746 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method in presence of 50% human serum | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID433234 | Antifungal activity against Candida glabrata 570 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID545201 | Antimicrobial activity against Candida albicans isolate R at 25 ug/ml grown on RPMI 1640 medium after 48 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID516174 | Antifungal activity against Candida albicans K1 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID433677 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 13 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-210 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432492 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as prolongation of fungal growth suppression at 20 mg/kg, ip administered 2 hrs postinfection as single dose by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574322 | Fungicidal activity against Candida albicans isolate 2 assessed as log reduction in bacterial count at 16 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522777 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 0.25 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID433628 | Antifungal activity against Candida glabrata 5592 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432318 | Elimination half life in serum of neutropenic ICR/Swiss mouse candidiasis model at 20 mg/kg, ip by reverse-phase high-pressure liquid chromatography | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374491 | Antifungal activity against Candida parapsilosis isolate 0011-013 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID522740 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 16 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID559660 | Fungicidal activity against Candida krusei EU220 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID433637 | Antifungal activity against Candida glabrata 513 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570853 | Increase in susceptibility to SDS in Candida parapsilosis isolate 1 assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522753 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 1 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID323264 | Antifungal activity against Candida albicans SCS67023C after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID518084 | Fungistatic activity against Candida glabrata infected in neutropenic ICR Swiss mouse after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID432627 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as viral burden per kidney administered intraperitoneally every 48 hrs up to 4 days measured per 96 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432837 | Ratio of free-drug Cmax in Candida glabrata 34341-infected neutropenic ICR/Swiss mouse candidiasis model at 6.9 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 34341 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID518071 | Ratio of AUC (0 to 24 hrs) in Candida albicans infected neutropenic ICR Swiss mouse to MIC for Candida albicans at static dose after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID571052 | Antifungal activity against Candida glabrata assessed as time period for bacterial regrowth inhibition after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID324343 | Inhibition of glucan synthase in Candida albicans SC5314 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID432514 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 3.90 +/- 0.15 log10CFU per kidney administered intraperitoneally every 16 hrs up to 4 days me | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544406 | Selectivity ratio of Ki for Candida albicans 119 1,3-beta-D-glucan synthase subunit FKS1p T1921C mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID324313 | Ratio of MIC for Candida albicans to MIC for Candida albicans in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID559654 | Fungicidal activity against Candida krusei CK6 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID543919 | Antimicrobial activity against Candida albicans 36082 by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID324315 | Ratio of MIC for Candida krusei to MIC for Candida krusei in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID432497 | Fraction unbound in Candida albicans K-1 infected neutropenic ICR/Swiss mouse serum at 20 mg/kg, ip administered 2 hrs postinfection as single dose measured after 12 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544311 | Inhibition of human CYP1A2 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID433434 | Ratio of free-drug Cmax in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433646 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID518087 | Antifungal activity against Candida glabrata infected in neutropenic ICR Swiss mouse assessed log reduction in bacterial count after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID432310 | Antifungal activity against Candida glabrata 5592 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID540213 | Half life in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID432284 | Increase in metabolic activity of nongerminated Aspergillus flavus assessed as elongation of short, stubby aberrant hyphae at 16 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID433648 | Ratio of AUC (0 to 24 hrs) in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 2.31 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID545196 | Antimicrobial activity against Candida albicans isolate R at 1 ug/ml grown on Muller-Hinton agar medium after 24 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID522780 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 16 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID433446 | Ratio of free-drug Cmax in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 13 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433641 | Antifungal activity against Candida glabrata 34341 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID535407 | Antifungal activity against Candida albicans 32746 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID575114 | Antifungal activity against Madurella mycetomatis isolate 52 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID522769 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 4 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID540211 | Fraction unbound in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID432827 | Ratio of free-drug Cmax in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 6.8 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433022 | Ratio of AUC (0 to 24 hrs) in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.15 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID535627 | Inhibition of Candida tropicalis T19 blood stream isolate glucan synthase subunit FKS1p with FLTLS/PLRDP mutant at monophasic kinetics | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID555611 | Antimicrobial activity against Aspergillus ustus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID433064 | Ratio of free-drug AUC (0 to 24 hrs) in Candida tropicalis 98-234-infected neutropenic ICR/Swiss mouse candidiasis model at 3.81 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida tropicalis 98-234 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522793 | Antifungal activity against Candida albicans 205 harboring FKS1 T1933C mutant gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID522778 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 1 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID325034 | Ratio of MIC of FKS1 T2080K mutation containing Candida krusei 100 isolate to MIC of Candida krusei 98 isolate from acute myelogenous leukemia patient by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. |
| AID544319 | Inhibition of human CYP2C8 at 17.5 uM in presence of rosiglitazone | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID574097 | Antifungal activity against Candida albicans isolate 1 by CLSI M27-A3 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432471 | Drug level in Candida albicans K-1 infected neutropenic ICR/Swiss mouse serum at 1.25 mg/kg, ip administered 2 hrs postinfection as single dose | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323310 | Antifungal activity against Candida dubliniensis ANSA 23a after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID432512 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally once every 96 hrs measured per 96 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID559663 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID559664 | Fungicidal activity against Candida krusei ATCC 6258 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID554489 | Antifungal activity against crzA deficient Aspergillus fumigatus Af293 assessed as abnormal hyphal growth by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. |
| AID534347 | Antifungal activity against Candida albicans grown as planktonic cell after 24 hrs by XTT reduction assay | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. |
| AID522779 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 4 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID532043 | Antifungal activity against Lichtheimia corymbifera clinical isolate after 24 hrs by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. |
| AID522748 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 1 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID555622 | Antimicrobial activity against Paecilomyces lilacinus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID433243 | Ratio of Cmax in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 2.31 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570867 | Increase in susceptibility to calcofluor white in Candida parapsilosis isolate 1 assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID571047 | Inhibition of Candida glabrata isolate 1 adherence to human buccal epithelial cells at 4 times MIC after 1 hr by adherence assay relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433631 | Antifungal activity against Candida albicans K-1 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID509653 | Antimicrobial activity against caspofungin-resistant Candida albicans NR4 expressing heterozygous fsk1 mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID323277 | Antifungal activity against Candida albicans JIMS146204 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID374526 | Ratio of MIC50 for Aspergillus fumigatus isolate 0002-021 in presence of 50% human serum to MIC50 for Aspergillus fumigatus isolate 0002-021 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID432258 | Effect on Aspergillus terreus metabolic activity assessed number of twofold drug dilutions required for germinated fungal metabolic activity to nongerminated fungal metabolic activity | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID521322 | Antimicrobial activity against Aspergillus niger hyphae isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method in presence of voriconazole | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID522759 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 4 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID535630 | Inhibition of Candida albicans ATCC 90028 glucan synthase at monophasic kinetics | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID565357 | Antifungal activity against Candida dubliniensis 9456 after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID432631 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 3.90 +/- 0.15 log10CFU per kidney administered intraperitoneally once every 96 hrs measured p | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID45484 | In vitro antifungal activity against candida albicans | 1999 | Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13 | The synthesis of water soluble prodrugs analogs of echinocandin B. |
| AID522697 | Fungicidal activity against Candida parapsilosis isolate CP-301 bloodstream form by CLSI method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID544313 | Inhibition of human CYP2C8 using amodiaquine as a substrate | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID574098 | Antifungal activity against Candida albicans isolate 2 by CLSI M27-A3 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID559650 | Fungicidal activity against Candida krusei CK1 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID323308 | Antifungal activity against Candida dubliniensis AMCC after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID540212 | Mean residence time in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID522699 | Fungicidal activity against Candida parapsilosis ATCC 22019 bloodstream form by CLSI method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID518073 | Ratio of AUC (0 to 24 hrs) in Candida parapsilosis infected neutropenic ICR Swiss mouse to MIC for Candida parapsilosis at static dose after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID535415 | Antifungal activity against Candida albicans 5415 expressing FKS1 F645P/H mutant after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID323369 | Antifungal activity against Candida glabrata 05-761 isolate assessed as decrease in fungal turbidity in presence of 5% human serum by microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID522705 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as induction of miniparadoxical effect at 32 mg/L after 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID535614 | Antifungal activity against Candida albicans 5415 expressing FKS1 F645P/H mutant after 24 hrs by broth microdilution method in presence of 50% human serum | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID559872 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 50% fungal growth reduction at 2 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID432245 | Ratio of log2 of MEC for germinated Aspergillus fumigatus to log2 of MEC for nongerminated Aspergillus fumigatus | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID570859 | Increase in susceptibility to calcofluor white in Candida parapsilosis isolate A assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID570842 | Increase in susceptibility to SDS in Candida krusei isolate ATCC 6258 assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432825 | Ratio of free-drug Cmax in Candida glabrata 35315-infected neutropenic ICR/Swiss mouse candidiasis model at 6.4 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 35315 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433052 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 1.97 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 570 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID535416 | Antifungal activity against Candida albicans 42286 expressing wild type FKS1 after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID531149 | Antifungal activity against Candida albicans M122 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID575108 | Antifungal activity against Madurella mycetomatis isolate 41 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID433070 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 35315-infected neutropenic ICR/Swiss mouse candidiasis model at 6.4 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 35315 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433058 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 3.57 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5592 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433615 | Ratio of antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model at 320 mg/kg/96 hrs, ip for 4 days to 1.25 mg/kg/96 hrs, ip for 4 days | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433680 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 4.13 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 513 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544179 | Activity at Candida albicans 3795 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID565387 | Antifungal activity against Candida dubliniensis FMR 10032 infected in OF1 mouse assessed as fungal count in kidney at 10 mg/kg/day, iv after 24 hrs by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID432313 | Cmax in serum of neutropenic ICR/Swiss mouse candidiasis model at 80 mg/kg, ip up to 4 hrs by reverse-phase high-pressure liquid chromatography | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323322 | Antifungal activity against Candida dubliniensis KR after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID432671 | Ratio of Cmax in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 6.8 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323260 | Antifungal activity against Candida albicans SC5314 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID522698 | Fungicidal activity against Candida parapsilosis isolate CP-302 bloodstream form by CLSI method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID323279 | Antifungal activity against Candida albicans NCPF6525 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID545150 | Antimicrobial activity against Candida albicans isolate R at 0.5 ug/ml after 48 hrs by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID518789 | Antifungal activity against Candida albicans expressing fks1 F641S mutant after 24 to 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. |
| AID509651 | Antimicrobial activity against caspofungin-resistant Candida albicans NR2 expressing heterozygous fsk1 mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID516182 | Antifungal activity against Candida glabrata 5376 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID559874 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 99% fungal growth reduction at 2 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID559665 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 50% fungal growth reduction at 0.12 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID559649 | Antifungal activity against Candida krusei CK1 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID432499 | Fraction unbound in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse serum at 5 mg/kg, ip administered 2 hrs postinfection as single dose | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570841 | Increase in susceptibility to SDS in Candida glabrata isolate 3 assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID374344 | Antifungal activity against Candida glabrata isolate 0049-038 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID516183 | Antifungal activity against Candida glabrata 34341 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID433444 | Ratio of free-drug Cmax in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323362 | Antifungal activity against Candida glabrata 05-761 isolate assessed as decrease in fungal turbidity in presence of 5% mouse serum by microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID574124 | Fungicidal activity against Candida parapsilosis isolate 1 assessed as log reduction in bacterial count at MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID535629 | Inhibition of Candida tropicalis T26 blood stream isolate glucan synthase subunit FKS1p with LLTLSLRDP mutant at monophasic kinetics | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID433431 | Ratio of free-drug Cmax in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 3.31 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323330 | Antifungal activity against Candida dubliniensis SCS17154969-2 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID564254 | Elimination half life in healthy human at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID518085 | Fungistatic activity against Candida parapsilosis infected in neutropenic ICR Swiss mouse after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID545193 | Antimicrobial activity against Candida albicans isolate R at 1 ug/ml grown on RPMI 1640 medium after 24 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID564445 | Drug level healthy human epithelial lining fluid at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions after 12 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID433620 | Antifungal activity against Candida tropicalis 98-234 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID543917 | Antimicrobial activity against Candida albicans SC5314 by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID574353 | Antifungal activity against Candida krusei isolate ATCC 6258 assessed as time period for bacterial growth inhibition at 4 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID570843 | Increase in susceptibility to SDS in Candida albicans isolate 1 assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID531150 | Antifungal activity against Candida glabrata ATCC 90030 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID433860 | Plasma protein binding in patient with serious fungal disease by ultrafiltration | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID516203 | AUC (0 to 24 hrs) in Candida albicans infected neutropenic ICR Swiss mouse at 80 mg/kg, ip | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID559031 | Plasma concentration in mouse infected with Candida albicans at 10 mg/kg, ip after 6 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID545197 | Antimicrobial activity against Candida albicans isolate R at 5 ug/ml grown on Muller-Hinton agar medium after 24 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID323304 | Antifungal activity against Candida dubliniensis 90/033 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID549037 | Antimicrobial activity against Candida krusei by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. |
| AID324320 | Inhibition of glucan synthase in Candida albicans 36082 assessed as incorporation of [3H]uridine diphosphoglucose in presence of 20% serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID433033 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 6.8 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433633 | Antifungal activity against Candida albicans 98-210 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323321 | Antifungal activity against Candida dubliniensis KR after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID509652 | Antimicrobial activity against caspofungin-resistant Candida albicans NR3 expressing homozygous fsk1 mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID433236 | Antifungal activity against Candida glabrata 33609 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432516 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per 96 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432498 | Fraction unbound in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse serum at 1.25 mg/kg, ip administered 2 hrs postinfection as single dose | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522711 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as induction of fungal killing rate at 0.03 to 32 mg/L measured at 6 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID47094 | In vitro antifungal activity against candida albicans after intraperitoneal administration of the compound | 1999 | Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13 | The synthesis of water soluble prodrugs analogs of echinocandin B. |
| AID543921 | Antimicrobial activity against Candida albicans 90028 by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID531146 | Antifungal activity against Candida albicans Sc5314 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID433246 | Ratio of Cmax in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 4.21 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID516404 | AUC (0 to 24 hrs) in Candida albicans infected neutropenic ICR Swiss mouse at 5 mg/kg, ip | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID323270 | Antifungal activity against Candida albicans B06-341 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID323282 | Antifungal activity against Candida albicans T28 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID544419 | Selectivity ratio of Ki for Candida albicans A15-10 1,3-beta-D-glucan synthase subunit FKS1p T1933C mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID323366 | Antifungal activity against Candida glabrata 05-62 isolate after 2 hrs in presence of 5% mouse serum by XTT reduction assay | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID522742 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 0.25 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID545210 | Antimicrobial activity against Candida albicans isolate S at 25 ug/ml grown on Muller-Hinton agar medium after 24 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID323289 | Antifungal activity against Candida albicans NR4 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID509644 | Antimicrobial activity against caspofungin-resistant Candida albicans NR4 expressing heterozygous fsk1 mutant gene by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID433221 | Ratio of free-drug AUC (0 to 24 hrs) in Candida tropicalis 98-234-infected neutropenic ICR/Swiss mouse candidiasis model at 3.81 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida tropicalis 98-23 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574105 | Antifungal activity against Candida krusei isolate ATCC 6258 by CLSI M27-A3 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433661 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 4.21 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID546080 | Antifungal activity against Candida pulcherrima isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID509656 | Antimicrobial activity against caspofungin-susceptible Candida krusei CY-118 by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID545151 | Antimicrobial activity against Candida albicans isolate R after 48 hrs by EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID433687 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 13 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-210 aft | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID535423 | Antifungal activity against Candida albicans 41509 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method in presence of 50% human serum | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID113164 | In vivo antifungal activity administered intraperitoneally against Candida albicans infections in mice. | 1995 | Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17 | Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. |
| AID570869 | Increase in susceptibility to calcofluor white in Candida glabrata isolate 3 assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433449 | Ratio of free-drug Cmax in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 4.13 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432483 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as suppression of fungal regrowth at 20 mg/kg, ip administered 2 hrs postinfection as single dose by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID571051 | Antifungal activity against Candida glabrata isolate 1 coincubated with mouse J774 macrophages assessed as macrophage induced bacterial cell killing at 4 times MIC (Rvb = 12 +/- 10 %) | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID323323 | Antifungal activity against Candida dubliniensis Leic875 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID432663 | Ratio of Cmax in Candida tropicalis 98-234-infected neutropenic ICR/Swiss mouse candidiasis model at 3.81 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida tropicalis 98-234 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374514 | Ratio of MIC50 for Aspergillus niger isolate 0001-073 in presence of 50% human serum to MIC50 for Aspergillus niger isolate 0001-073 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID374528 | Antifungal activity against Aspergillus flavus isolate 0001-033 after 24 hrs by CLSI M38-A broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID432261 | Effect on Aspergillus flavus metabolic activity assessed number of twofold drug dilutions required for germinated fungal metabolic activity to nongerminated fungal metabolic activity | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID433409 | Ratio of Cmax in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 4.13 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374498 | Antifungal activity against Candida parapsilosis isolate 0036-030 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID432819 | Ratio of free-drug Cmax in Candida tropicalis 98-234-infected neutropenic ICR/Swiss mouse candidiasis model at 3.81 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida tropicalis 98-234 after 24 hr | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544143 | Antimicrobial activity against Candida albicans 122 harboring FKS1 C1946A mutant gene and FKS1 hotspot1 P649H mutant gene by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID432652 | Ratio of Cmax in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 2.45 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID546078 | Antifungal activity against Candida kefyr isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID433232 | Antifungal activity against Candida albicans 98-210 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID571053 | Antifungal activity against Candida krusei assessed as time period for bacterial regrowth inhibition after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID582586 | Inhibition of Candida glabrata isolate 41026 1,3-beta-D-glucan synthase wild type Fks1p/Fks2p F659S mutant | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID433044 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 35315-infected neutropenic ICR/Swiss mouse candidiasis model at 6.4 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 35315 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433420 | Ratio of free-drug Cmax in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 4.21 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID518783 | Antifungal activity against Candida tropicalis isolate 4748 expressing fks1 F641S mutant after 24 to 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. |
| AID432495 | Fraction unbound in Candida albicans K-1 infected neutropenic ICR/Swiss mouse serum at 1.25 mg/kg, ip administered 2 hrs postinfection as single dose | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544407 | Selectivity ratio of Ki for Candida albicans 177 1,3-beta-D-glucan synthase subunit FKS1p T1922C mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID516171 | Antifungal activity against Candida albicans 98-210 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID522727 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 0.25 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID374517 | Ratio of MIC50 for Aspergillus fumigatus isolate 0002-0016 in presence of 50% human serum to MIC50 for Aspergillus fumigatus isolate 0002-0016 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID432667 | Ratio of Cmax in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 1.58 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433654 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 7.5 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID565368 | Antifungal activity against Candida dubliniensis 9453 by hemocytometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID544416 | Selectivity ratio of Ki for Candida albicans 194 1,3-beta-D-glucan synthase subunit FKS1p C1934T/G4082R mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID522714 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as induction of maximal fungal death at 1 mg/L after 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID531143 | Antifungal activity against Saccharomyces cerevisiae BY4742 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID433426 | Ratio of free-drug Cmax in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 13 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433029 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 1.58 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433210 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 2.45 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 513 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432832 | Ratio of free-drug Cmax in Candida tropicalis 98-234-infected neutropenic ICR/Swiss mouse candidiasis model at 3.81 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida tropicalis 98-234 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432637 | Antifungal activity against Candida tropicalis 98-234 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 3.81 +/- 0.33 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 day | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374523 | Ratio of MIC50 for Aspergillus fumigatus isolate 0002-020 in presence of 50% human serum to MIC50 for Aspergillus fumigatus isolate 0002-020 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID433211 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 33609 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID532045 | Antifungal activity against Lichtheimia ornata clinical isolate after 24 hrs by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. |
| AID433054 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 33609 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID374489 | Antifungal activity against Candida parapsilosis isolate 0014-074 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID522733 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 1 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID323290 | Antifungal activity against Candida albicans NR4 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID323333 | Antifungal activity against Candida dubliniensis SCS65875C after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID545015 | Mean residence time in human plasma at 100 mg, iv by LC-MS/MS analysis | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID433247 | Ratio of Cmax in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 3.31 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID529450 | Antifungal activity against Candida sp. | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Pharmacokinetics and tissue distribution of anidulafungin in rats. |
| AID545017 | Clearance in human plasma at 100 mg, iv by LC-MS/MS analysis | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID549018 | Antimicrobial activity against Candida krusei LMR 39-14 infected in immunosuppressed CF-1 mouse assessed as decrease in kidney bacterial burden at 10 mg/kg, ip administered once daily for 5 days measured after 5 days (Rvb= 6.66) | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. |
| AID574122 | Fungicidal activity against Candida parapsilosis isolate 1 assessed as log reduction in bacterial count at 16 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID582490 | Antifungal activity against Candida glabrata isolate 21900 expressing Fks1p D632G mutant and wild type Fks2p by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID432319 | Cmax in serum of neutropenic ICR/Swiss mouse candidiasis model at 5 mg/kg, ip up to 4 hrs by reverse-phase high-pressure liquid chromatography | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432255 | Effect on Aspergillus fumigatus metabolic activity assessed number of twofold drug dilutions required for germinated fungal metabolic activity to nongerminated fungal metabolic activity | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID433061 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.15 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-17 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID565381 | Antifungal activity against Candida dubliniensis 9453 assessed as compound concentration at which paradoxical growth of observed after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID516188 | Antifungal activity against Candida parapsilosis 20385.079 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID570870 | Increase in susceptibility to calcofluor white in Candida krusei isolate ATCC 6258 assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432655 | Ratio of Cmax in Candida glabrata 34341-infected neutropenic ICR/Swiss mouse candidiasis model at 6.9 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 34341 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID571055 | Antifungal activity against Candida albicans assessed as time period for bacterial regrowth inhibition after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID323360 | Antifungal activity against Candida glabrata 05-761 isolate infected ICR mouse kidney assessed as reduction of tissue fungal burden at 5 mg/kg, ip | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID432865 | Ratio of free-drug Cmax in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 3.57 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522723 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 1 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID532042 | Antifungal activity against Lichtheimia ramosa clinical isolate after 48 hrs by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. |
| AID516186 | Antifungal activity against Candida parapsilosis 20450.096 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID432281 | Increase in metabolic activity of germinated Aspergillus fumigatus assessed as elongation of short, stubby aberrant hyphae at 16 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID432415 | Antifungal activity against nongerminated Aspergillus fumigatus assessed as absence of visual fungal growth at 64 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID323368 | Antifungal activity against Candida glabrata 05-62 isolate assessed as decrease in fungal turbidity in presence of 50% human serum by microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID432317 | AUC (0 to infinity) in serum of neutropenic ICR/Swiss mouse candidiasis model at 20 mg/kg, ip by reverse-phase high-pressure liquid chromatography | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433623 | Antifungal activity against Candida glabrata 33609 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID324331 | Inhibition of glucan synthase in Aspergillus fumigatus ATCC 13073 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID432244 | Antifungal activity against germinated Aspergillus fumigatus assessed as lowest drug concentration that produced short, stubby and highly branched hyphae after 48 hrs by microscopic analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID432824 | Ratio of free-drug Cmax in Candida glabrata 34341-infected neutropenic ICR/Swiss mouse candidiasis model at 6.9 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 34341 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432834 | Ratio of free-drug Cmax in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 2.45 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570855 | Increase in susceptibility to SDS in Candida glabrata isolate 3 assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID570832 | Antifungal activity against Candida parapsilosis isolate 1 assessed as time period for bacterial growth inhibition at 16 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433235 | Antifungal activity against Candida glabrata 513 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574331 | Fungicidal activity against Candida parapsilosis isolate S assessed as log reduction in bacterial count at 16 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID535408 | Antifungal activity against Candida albicans 4254 expressing FKS1 F641S mutant after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. |
| AID516204 | AUC (0 to 24 hrs) in Candida albicans infected neutropenic ICR Swiss mouse at 20 mg/kg, ip | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID531339 | Antimicrobial activity against Candida glabrata isolate 7755 expressing FKS2 F659V mutant gene after 24 hrs by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. |
| AID432275 | Increase in metabolic activity of germinated Aspergillus fumigatus assessed as elongation of short, stubby aberrant hyphae at 2 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID559025 | Plasma concentration in mouse infected with Candida albicans at 5 mg/kg, ip after 3 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID582572 | Antifungal activity against Candida glabrata isolate 41400 expressing wild type Fks1p and Fks2p D666G mutant by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID570852 | Increase in susceptibility to SDS in Candida parapsilosis isolate A assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID574095 | Antifungal activity against Candida albicans isolate S by CLSI M27-A3 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID549023 | Antimicrobial activity against Candida krusei LMR 39-14 infected in immunosuppressed CF-1 mouse assessed as decrease in kidney bacterial burden at 20 mg/kg, ip administered once daily for 5 days measured after 10 days (Rvb= 5.22) | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. |
| AID433856 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 11.8 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5592 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433416 | Ratio of free-drug Cmax in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 13 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433067 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 33609 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432489 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as prolongation of fungal growth suppression at 20 mg/kg, ip administered 2 hrs postinfection as single dose by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433071 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 3.57 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5592 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574125 | Fungicidal activity against Candida parapsilosis isolate S assessed as log reduction in bacterial count at 16 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID531142 | Antifungal activity against Candida metapsilosis 960161 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID522735 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 16 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID522738 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 99.9% reduction in fungal growth at 1 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID433666 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.95 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-17 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432835 | Ratio of free-drug Cmax in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 33609 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432267 | Induction of maximal metabolic inhibition in germinated Aspergillus flavus assessed as minimal metabolic activity Ymin after 2 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID509648 | Antimicrobial activity against caspofungin-resistant Candida albicans CAI4R1 expressing heterozygous fsk1 mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID544139 | Antimicrobial activity against Candida albicans 85 harboring FKS1 C1934T mutant gene and FKS1 hotspot1 S645F mutant gene by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID544334 | Ratio of AUC in blood to plasma for Sprague-Dawley at 5 mg/kg, iv by liquid scintillation counting | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID582571 | Antifungal activity against Candida glabrata isolate 3830 expressing wild type Fks1p and Fks2p S663P mutant by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID535616 | Antifungal activity against Candida tropicalis ATCC 750 | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID544414 | Selectivity ratio of Ki for Candida albicans 122 1,3-beta-D-glucan synthase subunit FKS1p C1946A mutant to Ki for Candida albicans SC5314 wild type 1,3-beta-D-glucan synthase subunit FKS1p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID323311 | Antifungal activity against Candida dubliniensis B71507 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID544172 | Inhibition of Candida albicans A15 1,3-beta-D-glucan synthase subunit FKS1p T1933Y mutant | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID582489 | Antifungal activity against Candida glabrata isolate 5847 expressing Fks1p S629P mutant and wild type Fks2p by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID582591 | Inhibition of Candida glabrata isolate 5416 1,3-beta-D-glucan synthase wild type Fks1p/Fks2p W1375L mutant | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID433645 | Antifungal activity against Candida glabrata 37661 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432266 | Induction of maximal metabolic inhibition in nongerminated Aspergillus flavus assessed as minimal metabolic activity Ymin after 2 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID433244 | Ratio of Cmax in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 3.72 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 570 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323325 | Antifungal activity against Candida dubliniensis Leic952 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID532046 | Antifungal activity against Lichtheimia ornata clinical isolate after 48 hrs by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. |
| AID549027 | Antimicrobial activity against Candida krusei LMR 39-14 infected in immunosuppressed CF-1 mouse assessed as serum 1,3-beta-D-glucan level at 20 mg/kg, ip administered once daily for 5 days measured after 5 days (Rvb= 5.22) | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. |
| AID326118 | Paradoxical effect in Candida tropicalis assessed as increase in turbidity at 16 times MIC | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. |
| AID432481 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as reduction of viral burden in kidney at 5 mg/kg, ip administered 2 hrs postinfection as single dose measured within 1 to 4 hrs post dosi | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID521314 | Antimicrobial activity against Aspergillus niger conidia isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method in presence of voriconazole | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID574324 | Fungicidal activity against Candida albicans isolate 2 assessed as log reduction in bacterial count at MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432260 | Effect on germinated Aspergillus flavus metabolic activity assessed as drug concentration at which fungal metabolic activity occurs after 2 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID522797 | Inhibition of Candida glabrata CG-C2 FKS1 T1885C mutant | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID522790 | Antifungal activity against Candida glabrata CG-C3 harboring FKS2 T1987C mutant gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID432305 | Antifungal activity against Candida glabrata 33609 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as fungal count per kidney administered 2 hrs postinfection measured up to 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432851 | Ratio of free-drug Cmax in Candida glabrata 353205-infected neutropenic ICR/Swiss mouse candidiasis model at 6.4 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 353205 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID324327 | Inhibition of glucan synthase in Aspergillus fumigatus MF5668 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID545285 | Antimicrobial activity against Candida albicans isolate S at 25 ug/ml grown on Muller-Hinton agar medium after 48 hrs by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID574339 | Fungicidal activity against Candida glabrata isolate 3 assessed as log reduction in bacterial count at 16 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID531148 | Antifungal activity against Candida albicans ATCC 36082 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID549036 | Antimicrobial activity against Candida krusei LMR 39-14 by M27-A3 microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. |
| AID323276 | Antifungal activity against Candida albicans JIMS132203 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID544312 | Inhibition of human CYP2B6 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID559880 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 50% fungal growth reduction at 8 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID433065 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 1.97 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 570 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID326121 | Paradoxical effect in Candida krusei assessed as increase in turbidity at 16 times MIC | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. |
| AID529545 | Antifungal activity against Candida glabrata 06-3169 harboring FSK1p T1896G and D632E mutant obtained from patient on compound therapy by M27-A2 method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. |
| AID432644 | Antifungal activity against Candida glabrata 5592 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 1.83 +/- 0.54 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days me | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574352 | Antifungal activity against Candida glabrata isolate 3 assessed as time period for bacterial growth inhibition at 4 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433853 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 4.13 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 513 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323292 | Antifungal activity against Candida albicans CAI4RI after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID433055 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 1.58 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 32930 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522706 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as induction of miniparadoxical effect at 32 mg/L after 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID433866 | Ratio of antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model at 320 mg/kg, ip administered every 16 hrs up to 4 days to at 1.25 mg/kg, ip administered every 16 hrs up to 4 days | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323263 | Antifungal activity against Candida albicans SCS67023C after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID544131 | Antimicrobial activity against Candida albicans 2762 harboring FKS1 T1922C mutant gene and FKS1 hotspot1 F641S mutant gene by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID570876 | Increase in susceptibility to calcofluor white in Candida glabrata isolate 3 assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID518083 | Fungistatic activity against Candida albicans infected in neutropenic ICR Swiss mouse after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID433442 | Ratio of free-drug Cmax in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 11.8 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522765 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 16 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID323272 | Antifungal activity against Candida albicans HK04M102095 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID522749 | Antifungal activity against Candida metapsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 4 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID518794 | Antifungal activity against Candida glabrata after 24 to 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. |
| AID323267 | Antifungal activity against Candida albicans AM2003/0083 after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID570868 | Increase in susceptibility to calcofluor white in Candida glabrata isolate 1 assessed as cell wall damage at 4 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID374519 | Antifungal activity against Aspergillus fumigatus isolate 0020-018 after 24 hrs by CLSI M38-A broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID433682 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 3.31 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 32930 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432487 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as suppression of fungal regrowth at 5 mg/kg, ip administered 2 hrs postinfection as single dose by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433861 | Antifungal activity against Candida albicans after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433435 | Ratio of free-drug Cmax in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.95 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID323367 | Antifungal activity against Candida glabrata 05-62 isolate after 2 hrs in presence of 50% mouse serum by XTT reduction assay | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID521312 | Antimicrobial activity against Aspergillus terreus conidia isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method in presence of voriconazole | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID522694 | Fungicidal activity against Candida metapsilosis isolate CP-133 bloodstream form by CLSI method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID582570 | Antifungal activity against Candida glabrata isolate 41026 expressing wild type Fks1p and Fks2p F659S mutant by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID582565 | Antifungal activity against Candida glabrata isolate 21900 expressing Fks1p D632G mutant and wild type Fks2p by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID531145 | Antifungal activity against FKS1 deficient Saccharomyces cerevisiae BY4742 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID433851 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 2.31 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans 580 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID518068 | Half life in Candida albicans infected neutropenic ICR Swiss mouse at 20 mg/kg, ip | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID324316 | Ratio of MIC for Candida parapsilosis to MIC for Candida parapsilosis in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID432838 | Ratio of free-drug Cmax in Candida glabrata 35315-infected neutropenic ICR/Swiss mouse candidiasis model at 6.4 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 35315 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574093 | Antifungal activity against Candida glabrata by NCCLS M27A broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID432852 | Ratio of free-drug Cmax in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 3.57 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433681 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 4.21 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 33609 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570872 | Increase in susceptibility to calcofluor white in Candida albicans ATCC 90028 assessed as cell wall damage at 16 times MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID374511 | Ratio of MIC50 for Aspergillus terreus isolate 0031-087 in presence of 50% human serum to MIC50 for Aspergillus terreus isolate 0031-087 in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID516172 | Antifungal activity against Candida albicans 580 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID522768 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 90% reduction in fungal growth at 1 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID433672 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 3.31 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 32930 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433031 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 35315-infected neutropenic ICR/Swiss mouse candidiasis model at 6.4 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 35315 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433423 | Ratio of free-drug Cmax in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 7.5 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID570861 | Increase in susceptibility to calcofluor white in Candida glabrata isolate 1 assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522722 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 0.25 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID323354 | Antifungal activity against Candida glabrata 05-62 isolate in presence of 50% mouse serum after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID425791 | Antifungal activity against Candida albicans M61 grown as biofilm assessed as 50% reduction in metabolic activity of biofilm after 24 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID522787 | Antifungal activity against Candida tropicalis CT-C1 harboring FKS1 T227C mutant gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID433233 | Antifungal activity against Candida albicans 580 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432818 | Ratio of free-drug Cmax in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 0.94 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans 580 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433673 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 11.8 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5592 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574092 | Antifungal activity against Candida albicans by NCCLS M27A broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID559653 | Antifungal activity against Candida krusei CK6 bloodstream forms after 24 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID323320 | Antifungal activity against Candida dubliniensis J931021 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID323338 | Antifungal activity against Candida dubliniensis ST after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID432823 | Ratio of free-drug Cmax in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 1.58 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574112 | Fungicidal activity against Candida albicans ATCC 90028 assessed as log reduction in bacterial count at MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID529557 | Antimicrobial activity against Candida albicans GDH2346 grown as sessile cell after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | In vitro activity of anidulafungin against Candida albicans biofilms. |
| AID516180 | Antifungal activity against Candida glabrata 33616 after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID324329 | Inhibition of glucan synthase in Aspergillus fumigatus MF5668 in presence of 20% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID433638 | Antifungal activity against Candida glabrata 33609 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432843 | Ratio of free-drug Cmax in Candida albicans 98-2200-infected neutropenic ICR/Swiss mouse candidiasis model at 3.37 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-2200 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID575106 | Antifungal activity against Madurella mycetomatis isolate 36 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID582568 | Antifungal activity against Candida glabrata isolate 31498 expressing wild type Fks1p and Fks2p F659 deletion mutant by CLSI method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID518077 | Ratio of AUC (0 to 24 hrs) in Candida albicans infected neutropenic ICR Swiss mouse to MIC for Candida albicans at 1 log kill dose after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID433224 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 33609-infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 33609 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID549019 | Antimicrobial activity against Candida krusei LMR 39-14 infected in immunosuppressed CF-1 mouse assessed as decrease in kidney bacterial burden at 20 mg/kg, ip administered once daily for 5 days measured after 5 days (Rvb= 5.22) | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. |
| AID574128 | Fungicidal activity against Candida glabrata isolate 1 assessed as log reduction in bacterial count at 16 times MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522701 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as fungal count at 4 mg/L measured at 6 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID544339 | Half life in human plasma at 100 mg, iv by LC-MS/MS analysis | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. |
| AID574090 | Antifungal activity against Candida krusei by NCCLS M27A broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522726 | Antifungal activity against Candida orthopsilosis clinical isolate bloodstream form assessed as time required for 50% reduction in fungal growth at 32 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID518082 | Ratio of fAUC (0 to 24 hrs) in Candida parapsilosis infected neutropenic ICR Swiss mouse to MIC for Candida parapsilosis at 1 log kill dose after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID575119 | Antifungal activity against Madurella mycetomatis isolate 73 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID559881 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 90% fungal growth reduction at 8 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID516201 | Cmax in Candida albicans infected neutropenic ICR Swiss mouse at 20 mg/kg, ip | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID432650 | Ratio of Cmax in Candida tropicalis 98-234-infected neutropenic ICR/Swiss mouse candidiasis model at 3.81 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida tropicalis 98-234 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433027 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 2.45 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433656 | Ratio of AUC (0 to 24 hrs) in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.95 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID529451 | Antifungal activity against Aspergillus fumigatus | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Pharmacokinetics and tissue distribution of anidulafungin in rats. |
| AID323332 | Antifungal activity against Candida dubliniensis SCS59662 after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID432836 | Ratio of free-drug Cmax in Candida glabrata 32930-infected neutropenic ICR/Swiss mouse candidiasis model at 1.58 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 32930 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID559020 | Antifungal activity against Candida albicans infected in mouse assessed as decrease in fungal load in brain at 5 mg/kg, ip after 10 days | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin treatment of candidal central nervous system infection in a murine model. |
| AID433207 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 580-infected neutropenic ICR/Swiss mouse candidiasis model at 0.94 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida albicans 580 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID522789 | Antifungal activity against Candida glabrata CG-C2 harboring FKS1 T1885C mutant gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Novel FKS mutations associated with echinocandin resistance in Candida species. |
| AID433425 | Ratio of free-drug Cmax in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.95 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID521307 | Antimicrobial activity against Aspergillus fumigatus conidia isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID432269 | Increase in metabolic activity of germinated Aspergillus fumigatus assessed as formation of short, stubby aberrant hyphae at 0.03 ug/mL after 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID432243 | Antifungal activity against nongerminated Aspergillus fumigatus assessed as lowest drug concentration that produced short, stubby and highly branched hyphae after 48 hrs by microscopic analysis | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. |
| AID433660 | Ratio of AUC (0 to 24 hrs) in Candida glabrata 513-infected neutropenic ICR/Swiss mouse candidiasis model at 4.13 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 513 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID582550 | Antifungal activity against Candida glabrata isolate 3169 expressing Fks1p D632E mutant and wild type Fks2p by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID432491 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as prolongation of fungal growth suppression at 1.25 mg/kg, ip administered 2 hrs postinfection as single dose by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544152 | Antimicrobial activity against Candida albicans A15-10 harboring FKS1 T1933C mutant gene and FKS1 hotspot1 S645P mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID323291 | Antifungal activity against Candida albicans CAI4RI after 24 hrs by CLSI M27-A test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID570860 | Increase in susceptibility to calcofluor white in Candida parapsilosis isolate 1 assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID374332 | Antifungal activity against Candida parapsilosis isolate 0014-074 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID521310 | Antimicrobial activity against Aspergillus niger conidia isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID323359 | Antifungal activity against Candida glabrata 05-761 isolate infected ICR mouse kidney assessed as reduction of tissue fungal burden at 1 mg/kg, ip | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. |
| AID565366 | Antifungal activity against Candida dubliniensis 10035 after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. |
| AID575116 | Antifungal activity against Madurella mycetomatis isolate 55 by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. |
| AID433852 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 570-infected neutropenic ICR/Swiss mouse candidiasis model at 3.72 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 570 after 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID518080 | Ratio of fAUC (0 to 24 hrs) in Candida albicans infected neutropenic ICR Swiss mouse to MIC for Candida albicans at 1 log kill dose after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID432634 | Antifungal activity against Candida albicans 98-17 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 3.81 +/- 0.33 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days m | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID574127 | Fungicidal activity against Candida parapsilosis isolate S assessed as log reduction in bacterial count at MIC after 48 hrs by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID324347 | Ratio of MIC for Aspergillus fumigatus to MIC for Aspergillus fumigatus in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID433230 | Antifungal activity against Candida albicans K-1 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required for 1-log10 reduction in viral burden per kidney administered intraperitoneally every 24 hrs up to 4 days measured per 24 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID518069 | Half life in Candida albicans infected neutropenic ICR Swiss mouse at 5 mg/kg, ip | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. |
| AID574351 | Antifungal activity against Candida glabrata isolate 1 assessed as time period for bacterial growth inhibition at 4 times MIC after 1 hr drug exposure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID570863 | Increase in susceptibility to calcofluor white in Candida krusei isolate ATCC 6258 assessed as cell wall damage at MIC after 1 hr relative to control | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID433023 | Ratio of AUC (0 to 24 hrs) in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 3.37 mg/kg/24 hrs, ip for 4 days to MIC for complete growth inhibition of Candida albicans 98-210 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433696 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.95 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-17 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID543928 | Antimicrobial activity against Candida albicans 119 harboring FKS1 T1921C mutant gene and FKS1 hotspot1 F641L mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID432640 | Antifungal activity against Candida glabrata 33609 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as dose required to maintain viral burden of 1.83 +/- 0.54 log10CFU per kidney administered intraperitoneally every 24 hrs up to 4 days m | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433675 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida albicans K-1 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID372840 | Antifungal activity against Aspergillus flavus isolate 0001-061 after 24 hrs by CLSI M38-A broth microdilution method in presence of 50% human serum | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID433415 | Ratio of free-drug Cmax in Candida albicans 98-17-infected neutropenic ICR/Swiss mouse candidiasis model at 1.95 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans 98-17 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID582578 | Inhibition of Candida glabrata isolate 3168 wild type 1,3-beta-D-glucan synthase | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. |
| AID521313 | Antimicrobial activity against Aspergillus flavus conidia isolated from aspergillosis patient after 48 hrs under hypoxic condition by broth microdilution method in presence of voriconazole | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. |
| AID574325 | Fungicidal activity against Candida parapsilosis isolate A assessed as log reduction in bacterial count at 16 times MIC after drug exposure for 1 hr followed by washout measured after 48 hrs in the absence of drug by PAFE study | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID522775 | Antifungal activity against Candida parapsilosis clinical isolate bloodstream form assessed as time required for 99% reduction in fungal growth at 16 mg/L by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. |
| AID433850 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans 98-210-infected neutropenic ICR/Swiss mouse candidiasis model at 13 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for partial growth inhibition of Candida albicans 98-210 afte | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID432328 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as reduction of viral burden in kidney at 20 mg/kg, ip administered 2 hrs postinfection as single dose measured after 96 hrs post dosing b | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID544147 | Antimicrobial activity against Candida albicans 194 harboring FKS1 C1934T/G4082R mutant gene and FKS1 hotspot1 S645F mutant gene and FKS1 hotspot2 R1361R/H mutant gene by M27-A3 method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID374348 | Antifungal activity against Candida krusei ATCC 6258 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID432670 | Ratio of Cmax in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 3.57 mg/kg/24 hrs, ip for 4 days to MIC for partial growth inhibition of Candida glabrata 5592 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433632 | Antifungal activity against Candida albicans 98-17 assessed as complete growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID564448 | Drug level healthy human alveolar macrophage at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions after 8 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. |
| AID324318 | Inhibition of glucan synthase in Candida albicans 36082 assessed as incorporation of [3H]uridine diphosphoglucose | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Serum differentially alters the antifungal properties of echinocandin drugs. |
| AID544132 | Antimicrobial activity against Candida albicans 205 harboring FKS1 T1933C mutant gene and FKS1 hotspot1 S645P mutant gene by M27-A3 method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. |
| AID374500 | Antifungal activity against Candida parapsilosis ATCC 22019 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID432840 | Ratio of free-drug Cmax in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 6.8 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for partial growth inhibition of Candida glabrata 5376 after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433693 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5592-infected neutropenic ICR/Swiss mouse candidiasis model at 11.8 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5592 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433617 | Antifungal activity against Candida albicans 98-17 assessed as partial growth inhibition after 24 hrs by CLSI end point method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433674 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 7.5 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5376 after 2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID433665 | Ratio of free-drug AUC (0 to 24 hrs) in Candida albicans K-1 infected neutropenic ICR/Swiss mouse candidiasis model at 2 mg/kg/24 hrs, ip for 4 days using 1% free-drug concentration to MIC for complete growth inhibition of Candida albicans K-1 after 24 hr | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID571050 | Antifungal activity against Candida parapsilosis isolate 1 coincubated with mouse J774 macrophages assessed as macrophage induced bacterial cell killing at 4 times MIC (Rvb = 22 +/- 12 %) | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. |
| AID374524 | Antifungal activity against Aspergillus fumigatus isolate 0002-021 after 24 hrs by CLSI M38-A broth microdilution method in presence of RPMI 1640 medium | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Effects of serum on in vitro susceptibility testing of echinocandins. |
| AID531147 | Antifungal activity against Candida albicans ATCC 90028 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. |
| AID433216 | Ratio of free-drug AUC (0 to 24 hrs) in Candida glabrata 5376-infected neutropenic ICR/Swiss mouse candidiasis model at 6.8 mg/kg/24 hrs, ip for 4 days using 20% free-drug concentration to MIC for complete growth inhibition of Candida glabrata 5376 after | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID559864 | Antifungal activity against Candida krusei ATCC 6258 bloodstream forms assessed as time to achieve 50% fungal growth reduction at 0.5 mg/L by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| AID323334 | Antifungal activity against Candida dubliniensis SCS65875C after 24 hrs by EUCAST test | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. |
| AID432482 | Antifungal activity against Candida glabrata 5376 infected in neutropenic ICR/Swiss mouse candidiasis model assessed as reduction of viral burden in kidney at 1.25 mg/kg, ip administered 2 hrs postinfection as single dose measured within 1 to 4 hrs post d | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| AID509642 | Antimicrobial activity against caspofungin-resistant Candida albicans NR2 expressing heterozygous fsk1 mutant gene by CLSI M27-A3 broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. |
| AID1804171 | DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\ | 2020 | Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7 | Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 26 (4.71) | 18.2507 |
| 2000's | 163 (29.53) | 29.6817 |
| 2010's | 295 (53.44) | 24.3611 |
| 2020's | 68 (12.32) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (62.73) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 33 (5.81%) | 5.53% |
| Reviews | 95 (16.73%) | 6.00% |
| Case Studies | 46 (8.10%) | 4.05% |
| Observational | 3 (0.53%) | 0.25% |
| Other | 391 (68.84%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 Year [NCT01188759] | Phase 3 | 0 participants (Actual) | Interventional | 2012-05-31 | Withdrawn | ||
| Multicenter, Randomized, Open-label Clinical Trial to Compare Anidulafungin Versus Amphotericin B Safety in High Risk Hepatic Transplant Recipients [NCT01303549] | Phase 4 | 61 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Randomized Comparison of β-D-Glucan Surveillance With Preemptive Anidulafungin Versus Standard Care for the Management of Invasive Candidiasis in Surgical Intensive Care Unit Patients [NCT00672841] | 64 participants (Actual) | Interventional | 2008-06-30 | Completed | |||
| A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole [NCT05178862] | Phase 3 | 220 participants (Anticipated) | Interventional | 2022-08-03 | Suspended(stopped due to During a review of manufacturing equipment and cleaning activities at a supplier that manufactured study drug for this study, SCYNEXIS was made aware of potential cross-contamination risk with a non-antibacterial beta-lactam drug substance.) | ||
| Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole, For Treatment Of Documented Candidemia/Invasive Candidiasis In Hospitalized Patients [NCT00548262] | Phase 4 | 54 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis [NCT00496197] | Phase 4 | 282 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Phase IIIB Pilot Study Of Efficacy And Safety Of Anidulafungin In The Treatment Of Candidemia In Asian Patients [NCT00537329] | Phase 3 | 43 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations [NCT00689338] | Phase 3 | 216 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection [NCT00806351] | Phase 3 | 21 participants (Actual) | Interventional | 2009-08-31 | Terminated(stopped due to The study was prematurely terminated on May 18, 2012 due to slow enrollment. The study was not terminate due to any safety issues or concerns.) | ||
| Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Patients With Candida Deep Tissue Infection [NCT00805740] | Phase 3 | 41 participants (Actual) | Interventional | 2009-04-30 | Terminated(stopped due to The study was terminated prematurely on May 18, 2012 due to slow enrollment. The study was not terminated due to any safety issues or concerns.) | ||
| Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene Treatment [NCT00620074] | Phase 4 | 6 participants (Actual) | Interventional | 2008-08-31 | Terminated(stopped due to See Detailed Description) | ||
| A Phase 4, Open Label Study To Assess The Bronchopulmonary Pharmacokinetics Of Anidulafungin And Voriconazole Following Intravenous Administration In Healthy Subjects [NCT00940017] | Phase 4 | 24 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| The Pharmacokinetics of Anidulafungin During Continuous Venovenous Hemofiltration [NCT00892359] | Phase 2 | 10 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | ||
| A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIA [NCT00761267] | Phase 3 | 70 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Pharmacokinetics of Anidulafungin (Ecalta ®) Given Intravenously as Prophylaxis to Obese Patients With Risk of Invasive Fungal Infection Undergoing Gastric Bypass Surgery. [NCT02021123] | Phase 4 | 8 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive Aspergillosis [NCT00531479] | Phase 3 | 459 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Anidulafungin in Patients With Hematologic Malignancies - An Open-label, Prospective Study to Evaluate the Safety Profile at Prophylactic and Therapeutic Dosages [NCT01053884] | Phase 2 | 10 participants (Actual) | Interventional | 2009-10-31 | Terminated(stopped due to reduced recruitment rate due to non infectious, but competitive trials at our institution) | ||
| A Phase Iiib, Open-label, Randomized, Multi-center Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole, In The Treatment Of Subjects With Candidemia And/or Other Forms Of Invasive Candidiasis [NCT01176058] | Phase 3 | 17 participants (Actual) | Interventional | 2010-12-31 | Terminated(stopped due to See termination reason in detailed description.) | ||
| A Phase III, Double Blind, Randomized, Multi-Center Study of the Safety and Efficacy of Anidulafungin VS. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications [NCT00058682] | Phase 3 | 248 participants | Interventional | 2003-04-30 | Completed | ||
| Antimicrobial Pharmacokinetics in High Risk Infants (Urinary Proteomics in Antimicrobial/Antifungal-Treated Newborns - add-on Study) [NCT00491426] | 450 participants (Actual) | Observational | 2006-01-31 | Completed | |||
| Pharmacokinetics of Anidulafungin Given Intravenously as Antifungal Prophylaxis to Recipients of an Allogeneic Haematopoietic Stem Cell Transplant Following Myeloablative Chemotherapy or Patients Receiving Intensive Chemotherapy for AML-MDS [NCT01249820] | Phase 2 | 26 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Translational PKPD Modeling of Anti-infective Drugs in Children Treated in Pediatric Units on the Example of Selected Antibiotics and Antifungals. [NCT05426499] | 150 participants (Anticipated) | Observational | 2021-10-01 | Active, not recruiting | |||
| Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial [NCT00841971] | Phase 4 | 200 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Phase I-II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Neutropenia [NCT00068471] | Phase 1/Phase 2 | 0 participants | Interventional | 2003-07-31 | Completed | ||
| A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in ICU Patients [NCT01734525] | Phase 4 | 85 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Phase 2, Open-Label, Randomized, Dose-Ranging Study of the Safety and Efficacy of Intravenous Anidulafungin (VER002) in the Treatment of Patients With Invasive Candidiasis [NCT00037219] | Phase 2 | 120 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| A Phase 2 Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis. [NCT00041704] | Phase 2 | 19 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| A Phase III, Double-Blind, Randomized, Multi-Center, Study of the Safety and Efficacy of Anidulafungin vs. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications. [NCT00056368] | Phase 3 | 256 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome® [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis. [NCT00037206] | Phase 2/Phase 3 | 30 participants (Actual) | Interventional | 2002-05-31 | Completed | ||
| Phase I/II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Fever and Neutropenia [NCT00056381] | Phase 1/Phase 2 | 25 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| A Multicenter Cohort Study of the Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents [NCT01686607] | 40,110 participants (Actual) | Observational | 2012-10-01 | Completed | |||
| Population Pharmacokinetic Analysis of Anidulafungin in Normal, Overweight and Obese Volunteers [NCT01307930] | Phase 4 | 20 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Study To Describe The Early Clinical Experience With Anidulafungin In Patients With Liver Disease At King's College Hospital NHS Trust, London [NCT01202253] | 50 participants (Actual) | Observational | 2011-02-28 | Completed | |||
| Azole-echinocandin Combination Therapy for Invasive Aspergillosis A Randomized Pragmatic Superiority Trial [NCT04876716] | Phase 3 | 650 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment (The CANTREAT Study): A Prospective, Randomized, Double Blind, Placebo Controlled Pilot Study [NCT00934934] | Phase 2 | 61 participants (Actual) | Interventional | 2010-04-30 | Terminated(stopped due to slow enrollment) | ||
| Anidulafungin PK in Infants and Toddlers [NCT00734500] | Phase 1 | 15 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||